Podcasts about ons

"If you are considering board service, I would say take the leap. Start with your local chapter. It will give you some valuable skills that will help prepare you when you are applying for your national level. And I always say, if you want to do it, just do it because what's the worst that can happen? They can say no, but that doesn't mean that you will never serve on a board. I always tell people delayed is not denied," Cassandra Green, DNP, RN, OCN®, ONS member and past president of the Oncology Nursing Certification Corporation (ONCC) Board of Directors, told Evelyn Wempe, DNP, MBA, APRN, ACNP-BC, AOCNP®, CRN, NEA-BC, chair of the ONS Leadership Succession Committee (formerly known as the Leadership Development Committee), during a conversation about service on a board of directors. Wempe spoke with Green and ONS members Kristin Ferguson, DNP, MBA, RN, OCN®, CGNC, former treasurer and director-at-large on the ONS Board of Directors, and Yanka Campbell, DNP, RN, CPHQ, AGPCNP-BC, CNE, member of the Oncology Nursing Foundation (ONF) Board of Directors, about their experiences with board service. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 28, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to serving on a board of directors for a professional organization. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Meet the ONS Board of Directors series Episode 342: What It's Like to Serve on the Leadership Development Committee ONS Voice articles: Could Today Be the Start of Your ONS Leadership Journey? Nursing Leadership Unlocked Leading With Purpose Creates a Vision for the Future of Oncology Nursing ONS courses: A Guide to Chapter Leadership: Chapter President Training Board Leadership: Nurses in Governance Clinical Journal of Oncology Nursing article: Rearview Mirror Leadership: Looking Backward to Move Forward ONS Board Self-Assessment ONS Leadership ONCC Board of Directors ONF Leadership Your Roadmap to Future Service on the ONS Board of Directors ONS Leadership Learning Library To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Campbell: "Joining a board was a natural next step for me to maintain my connection to bedside nursing that I've loved for so many years, and to find a way to give back to advanced practice nurses as well in this role. The Oncology Nursing Society and Foundation were especially meaningful for me because I knew firsthand the importance of having scholarship, research, funding, and leadership development programs that can really change the trajectory of a nurse's career. I realized I wanted to help shape the opportunities that were available to me for future nurses, and I just did not want to continue to do that through one-on-one mentorships, which I have done extensively throughout my career, but find a way to help more broadly toward guiding organizational mission and strategic objectives." TS 7:20 Green: "Everyone was so welcoming on the board. Everyone was so friendly. One of the first things I remember our executive director Tony Ellis telling me is, 'Most of our new board members are really quiet and reserved at our first meeting. They just kind of keep things to themselves. They don't ask a lot of questions.' I don't know if they were prepared for me because I came in with guns a-blazing, and I had lots of questions. I was not quiet. I was very involved and very vocal. I still am, but that was one of the best experiences ever. Before that, I had never really been in a board setting other than my local chapter, and even then, I was just starting to be in that setting because I was the president of my local chapter and on the [ONCC] Board of Directors at the same time." TS 10:29 Ferguson: "A nonclinical mentor I would absolutely identify would be Alec Stone, who used to be the ONS director of public affairs. … He helped me to learn a lot about health policy and advocacy and the impact a nurse's voice can have. Learning how to speak about my experiences in health care in public by doing programs like the Nurses in Washington Internship … or ONS's Capitol Hill Days ended up giving me a lot more confidence that I didn't know I would have in expressing my point of view and being very open and collegial and expressing my opinions. … This really lent itself well to my future board experience because, as Cassandra mentioned, board members have to speak their mind and speak up at the meetings." TS 12:11 Campbell: "One of the most unexpected benefits was when I reached out to my executive leadership team at the Kimmel Cancer Center at Johns Hopkins and said, 'I'm being considered to serve on the ONF Board. This is going to require me taking time away from work to attend meetings, to attend some in-person meetings. And then it would be really wonderful at the institution if I'm able to also financially impact the nurses who need to benefit from what I've benefited from in my career.' Usually when you have those conversations, you are expecting to present a deck of PowerPoint slides to make your case, but the answer from my leadership team in participating in ONF and supporting the Board was an immediate yes. It was 'Yes, when can you start? Yes, what can we do to support you?' And really making sure that I had dedicated time to be fully present." TS 14:15 Ferguson: "There are many skills and experiences that can lend themselves to being a strong board member. … The ability to speak your mind clearly and express your thoughts, which really boils down to strong communication skills. We are lucky in our careers. We all have worked as nurses in different settings and health care, and nurses are naturally skilled and good at communication. We learn strategies like SBAR—situation, background assessment, recommendation. Nurses every day are communicating in their places of work, oftentimes with patients who are sick and need education, or perhaps with new nurses they're teaching or mentoring. And they are communicating with non-nurses, as well, and nonpatients, so clinical roles and nonclinical roles. So nurses already have a good understanding of best practices when it comes to communication, and this can lend itself well to any board position." TS 21:04 Green: "When you [come into a] leadership role, I think that's when we learn most about ourselves and what we expect. And be the leader type of leader that you want to be and the type of leader that you would like to work with so that you can make your experience valuable and pleasurable." TS 28:57

"They're really worried that radiation is going to be painful. So they come in for that first day of treatment very anxious. With our patients with brain cancer, we're using the masks on the table, and those masks are very tight and hold their heads very, very still. So they'll be very worried about being claustrophobic. We may start out the first day or two with a little bit of [lorazepam]. And they'll come to me and they'll say, 'This really hasn't been as bad as I thought it was going to be,'" ONS member Catherine McCluskey, BSN, RN, OCN®, ROCN™, radiation oncology staff nurse at Atrium Health Wake Forest Baptist in Winston-Salem, NC, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, who was the manager of oncology nursing practice at ONS at the time of the recording, during a conversation about radiation side effects in central nervous system (CNS) cancers. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 21, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the side effects of radiation to treat CNS cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Radiation Site-Specific Side Effects series Episode 306: Cancer Symptom Management Basics: CNS Toxicities ONS Voice articles: Augmented Reality Simulations Reduce Patient Anxiety by Teaching Them About Radiation Therapy CNS Survivorship Needs More Research, Funding, and Training, Expert Panel Says Here's What the Updated CTCAE Version 6.0 Means for Oncology Nurses Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education Hyperbaric Oxygen Therapy Shows Promise for Certain Radiation Side Effects ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: Indications of Targeted Radiotherapy to the Brain and Spine: 2025 ONS Congress® Session ONS ROCN™ Certification Review™ ONS/ONCC® Radiation Therapy Certificate™ Supporting Radiation Side Effect Management Through ONS Evidence-Based Resources: 2025 ONS Congress® Session Clinical Journal of Oncology Nursing articles: Implementing a Standardized Educational Tool for Patients With Brain Tumors Undergoing Concurrent Temozolomide and Radiation Therapy Radiation Necrosis: A Differential Diagnosis Dilemma The Neurocognitive Late Effects of Cranial Radiation Therapy: The Often-Unrecognized Outcomes Oncology Nursing Forum article: Symptom Clusters in Patients With Brain Tumors Undergoing Proton Beam Therapy ONS Huddle Cards: External Beam Radiation Proton Therapy Proton Therapy Radiation ONS Guidelines™ and Symptom Management Resources Cognitive impairment Fatigue Mucositis Radiodermatitis ONCC resources: Big List of CE Radiation Oncology Certified Nurse (ROCN™) Common Terminology Criteria for Adverse Events (CTCAE v6.0) Patient Health Questionnaire (PHQ-9 and PHQ-2) To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "With primary tumors—glioblastomas, astrocytoma, all of those types of cancerous primary CNS tumors, the tumors are not very well-defined. They have little tentacles that kind of go out, so doing something like Gamma Knife, which is very precise, is not as effective as an external beam because the external beam will deliver radiation to all those little tentacles that are out there in the brain. And with Gamma Knife, you really can't effectively do that." TS 2:34 "When we're doing radiation to the brain, fortunately there aren't that many acute toxicities involved. Sometimes they'll have some mild dermatitis. Usually, it's not very significant. They, like everyone else who gets radiation, will have fatigue. Usually once we get to the end of the second week of radiation, into the third week for our patients with primary CNS tumors—the hair loss—they'll start to notice hair loss just in the treatment area. But those are typical, the things that we've seen most. Sometimes we'll have patients who will experience some nausea, maybe a few headaches, but really the acute toxicities are not severe typically with our patients with brain tumors." TS 8:30 "[For] the fatigue, I tell patients to just listen to their bodies. We don't want them to be sedentary, and we want them to go out and continue living their lives. But I do warn them that the fatigue is pretty much common to all patients receiving radiation at various degrees, depending on the patient. I just tell them to do what they feel like doing, and then when they're tired to rest, and if they find themselves having a nap in the afternoon, that's okay." TS 13:51 "What I find with these patients in particular is that a lot of times, their first symptoms related to any type of cancer are CNS symptoms from brain metastasis. Our patients with lung cancer or melanoma—they come in through the emergency room for altered mental status or seizures or something like that. They find a mass in their brain, and then they find a mass on their lung, or they find masses everywhere. Typically, they want to treat the brain masses first before they start them on any kind of systemic treatment. And so, they'll come to us, and they're in shock. Everything's happened very quickly. They haven't had a chance to really catch their breath. They're overwhelmed. And so I try to make sure they understand that everyone that they see here is part of their team and is with them through this journey and they're not alone." TS 25:36 "A couple of years ago, ONS put out an email asking for people to volunteer to do a delineation study about the feasibility of doing a radiation oncology certified nursing exam. And I, just on a whim, responded to that email. It's not something I've ever done before, and thinking that I would not be put on the team. … And I thought, 'I don't have enough experience, I don't know what I'm doing, and they won't choose me.' And lo and behold, they put me on this role delineation study. … I have met so many incredible nurses with all kinds of experience. I've learned so much. It has opened up a lot of things for me and it's been really exciting, so all I can do is say take advantage of those opportunities when they come. Don't think that you don't know enough, because you know more than you think you do." TS 32:38 

"Measurable residual disease is where I think the terminology fits best in that, it is intended to measure the amount of cancer cells that are present in the blood or bone marrow at the time the sample was collected. We can identify one cancer cell in a million. Where that can be really valuable is when we start to think about the duration of treatments and the response to some of our treatments," ONS member Caitilin Murphy, DNP, APRN, FNP-BC, AOCNP®, chief nurse practitioner at Dana-Farber Cancer Institute in Boston, MA, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about chronic lymphocytic leukemia (CLL) treatment considerations for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD), including 45 minutes of pharmacotherapeutic content, by listening to the full recording and completing an evaluation at courses.ons.org by August 14, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to treatment of chronic lymphocytic leukemia. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 422: An Overview of Chronic Lymphocytic Leukemia for Oncology Nurses Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis Episode 184: Oncologic Emergencies 101: Tumor Lysis Syndrome ONS Voice articles: Fixed-Duration Therapy for CLL May Lower Cardiovascular Risks and Costs Less Than Continuous Treatment Individuals With CLL Face Increased Risk for Skin Cancer Master Hypersensitivity Reactions With These Strategies for Prevention and Management Patients With CLL Report Worse QoL and Other Factors Clinical Journal of Oncology Nursing articles:  Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Pseudohyperkalemia in Chronic Lymphocytic Leukemia: An Often Overlooked Clinical Entity Richter Transformation Arising From Chronic Lymphocytic Leukemia Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia ONS book: Site-Specific Cancer Series: Leukemia (first edition) ONS symptom management resources:  Fatigue Prevention of Bleeding Prevention of Infection: General Blood Cancer United: Chronic Lymphocytic Leukemia Treatment CLL Society: Patient Education Toolkit Lymphoma Research Foundation: Lymphoma Treatments Patient education sheets Acalabrutinib Ibrutinib Pirtobrutinib To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Blood work is a really nice way to evaluate if there is progression of the disease. And we evaluate their blood counts, specifically that complete blood count with a differential. We anticipate an elevated white count, and we anticipate that the absolute lymphocyte count is going to be elevated. That's characteristic of the disease. But what evolves and happens is that those numbers can rapidly change and what we get concerned about is if that white count—and the percentage of the absolute lymphocyte count specifically—starts to increase and double quickly." TS 5:52 "There are some components that help clinicians decide if we expect these things, this cadence of change to happen more readily, or if we feel really comfortable that the biology of the variants contributing to the type of CLL that each patient may have, they may not have that progression as quickly or at all. And so that kind of helps us in that follow-up and cadence. Oftentimes, we're checking blood work every three or six months. Some patients are on an annual interval of visits depending on that active surveillance. I think the other piece is that we have a relatively low threshold when there is a change in symptoms to just recheck those blood tests. It's nice that we can have a pretty readily available blood test to be able to give us a lot of information for these patients." TS 9:45 "When we think about CLL therapy, the old tried and true [treatments] still work: so, rituximab and obinutuzumab. And then we kind of start to think about pathways and the way, the mechanisms of which these treatments are integrated. We think about different pathways of how we can induce cell death, but also what are the potential side effects? What are the potential interactions?" TS 19:35 "I think a lot of this is about really having a clear understanding of the patient's goals and really being able to understand and align. I think we have a lot more data to provide guidance for those patients that really are wanting to know: What is my chance of overall survival? If I do this, does this mean that I don't need to ever be on treatment again? If I do it this way, does it mean that I have to come into clinic every week, or does it mean that I have to come in every week but I'm done? I do one year of treatment, and I don't have to think about treatment for a really long time based on some of these components that we can take into consideration." TS 24:36 "When we think about the B-cell lymphoma 2 (BCL-2) inhibitors, with venetoclax, I think the biggest component we think about is tumor lysis syndrome. It's so effective that these cancer cells release all of those electrolytes, potassium, phosphorus; you can see a rise in the lactate dehydrogenase and uric acid because those cells are breaking down. And so subsequently, that leads us to the consideration of, is the patient's kidney function able to clear it? And so a lot of frequent lab monitoring, a lot of hydration, supportive care with medications like ursodiol or allopurinol to really improve the ability to clear that cellular waste product so that it doesn't cause an oncologic emergency." TS 34:11

According to the Office for National Statistics, the number of births in the UK continues to fall. Experts are even talking about a “baby bust”, the opposite of the “baby boom”, to describe these statistics, which have reached the lowest level since records began in 1938. One explanation for this could be that people are having children later than previous generations, leaving them with a reduced fertility window. In 2020, the Office for National Statistics notes that the average age at which women become mothers is 30, compared with 26 in 1975. In addition to this, the latest ONS birth data, released in 2020, reveals that 28% of women have their first child after the age of 30 and 5% after the age of 40. Can you run into problems if you want to get pregnant after the age of 30? In under 3 minutes, we answer your questions! To listen to the last episodes, you can click here: ⁠Could intentional lazy parenting foster your child's independence?⁠ ⁠What causes tocophobia, the fear of pregnancy and childbirth?⁠ ⁠⁠⁠⁠Why do children have imaginary friends?⁠ A podcast written and realised by Amber Minogue. First Broadcast: 27/2/2023 Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us Fan MailPsalm 25:14 Die Here neem dié wat Hom dien, in sy vertroue en maak sy verbond aan hulle bekend. Daar is iets vreeslik lekker en aanloklik aan 'n geheim, nè? Om te wag dat iemand jou genoeg vertrou om een te deel, voel kompleet of jy op die drumpel van iets groots staan. Sodra jy deel word van daardie "binnekring", verander alles sommer dadelik. Gedurende die Tweede Wêreldoorlog was net 'n handjievol mense by Bletchley Park in Engeland vertrou met die oorlog se grootste geheim – die ontsyfering van Duitsland se Enigma-kodemasjien. Hulle was 'n klein, eksklusiewe groepie wat in die geheim gewerk het en die loop van die geskiedenis verander het.Geheime – die goeies altans – is presies so. Hulle het enorme krag om dinge te verander, maar nie almal weet daarvan nie. As jy daaroor dink, is dit juis wat 'n geheim 'n geheim maak.Psalm 25:14 sê: Die Here neem dié wat Hom dien, in sy vertroue en maak sy verbond aan hulle bekend.As jy die Here eer, is jy sy vriend. Hy vertrou jou met sy geheime en leer jou presies waarop jy in sy beloftes kan staatmaak.En in Christus word daardie waarheid selfs nog groter. Jesus het vir sy dissipels in Johannes 15:15 gesê: Ek noem julle vriende, omdat Ek alles wat Ek van my Vader gehoor het, aan julle bekend gemaak het.Deur ons geloof in Hom is ek en jy nie meer buitestanders nie. Ons is binnekringmense –welkom in die raadsaal van God Self. Dink net daaraan! Dit laat 'n mens se kop sommer draai.Moet dus nie tevrede wees met 'n geloof wat net op die oppervlak lê nie. Gee vandag 'n tree nader. Leef met ontsag vir Hom en ontdek die vreugde daarvan om God se vriend te wees - sy vennoot wat in sy binneste sirkel welkom is.Dit is Sy Woord. Vars … vir jou … vandag.Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

Dag sal kortliks in nag verander oor dele van Europa en die Noord-Atlantiese Oseaan vandag met miljoene wat bymekaar sal kom om 'n geskiedkundige sonsverduistering te aanskou. Die maan blokkeer die son vanaf Groenland en Ysland reguit deur Noord-Spanje. Die belangrikste kykplek, Reykjavik, sien sy eerste totale verduistering in meer as 70 jaar. Die hoof van die Fisika Departement by Unam, dr. Riaan Steenkamp, het met Kosmos 94.1 Nuus gepraat. Ons loop dit mis:

"God se adres is nie die materiële skure wat ons buite onsself oprig om ons angs te besweer nie; Sy woning is binne-in ons. Ons verwar dikwels die buitekant se akkumulasie met innerlike vervulling. Die ware kuns is om op te hou bou aan die skure daar buite, en te begin luister na die ruimte daar binne."

Al jaren vergaderen vakbonden, werkgevers en de overheid over sociaal-economische plannen. Maar wat gebeurt er achter de schermen als ze met elkaar aan tafel zitten? In de Rode Draad hebben we deze zomer een vierdelige serie over de Nederlandse Polder. Ons huidige minderheidskabinet heeft ze misschien wel harder nodig dan ooit. Dus hoeveel macht heeft de polder eigenlijk? In aflevering 2 spreker we met twee ervaringsdeskundigen. Jarenlang stonden zij met hun voeten in de klei van die polder. Bernard Wientjes, oud-voorzitter van VNO-NCW tussen 2005 en 2014, en Agnes Jongerius, oud-voorzitter van de FNV tussen 2005 en 2012, vertellen hoe het er destijds aan toe ging. Meer horen? Luister hier (https://open.spotify.com/episode/3nuSUabjJYOnTpC97XBVTy?si=83fc7ff3616d40a9) aflevering 1 van deze serie over de Nederlandse polder

11 Augustus 2026: Ons praat met ons verslaggewer op die toneel waar 14 mynerwerkers dood is. Die jongste oor watter passe oop en watter toe is weens sneeu. Die tweede kwartaal se indiensnemingstatistiek is pas bekend.

Send us Fan MailPsalm 51:12 Skep vir my 'n rein hart, o God, vernuwe my gees en maak my standvastig. Ons het almal al foute gemaak wat ons eerder sou wou uitwis. Jy het; ek het; keuses wat ons gemaak het en wens ons kon terugtrek. Maar hoe dikwels hou ons net aan om op dieselfde pad te loop - die een kompromie ná die ander - eerder as om te stop; om te draai en God om genade te smeek?Dit is presies wat met koning Dawid gebeur het. Hy het Batseba se skoonheid gesien, hy het haar begeer en hy het haar geneem. Ongeag die feit dat sy getroud was. Soos jy kan dink, was die gevolge verwoestend. Haar man, Uria, wat onskuldig was in die situasie, is vermoor. 'n Vrou se lewe is verwoes. 'n Koning se hart het verhard in sy rebellie teen God. En vir 'n tyd lank het Dawid aangegaan asof niks gebeur het nie. Klink dit vir jou bekend?God het die profeet Natan gestuur om Dawid tot sy sinne te bring. Dit was toe hy die verskriklikheid van sy dade verstaan het, dat Dawid vir God gevra het om hom te vergewe en hom rein te maak: Psalm 51:12: Skep vir my 'n rein hart, o God, vernuwe my gees en maak my standvastig.Dawid wou nie net vergifnis hê nie - hy wou sy verhouding met God herstel. Hy wou daardie vreugde van God se verlossing terughê. Die krag van sy Gees. Hy wou weer in gehoorsaamheid wandel.En dít is God se uitnodiging aan jou vandag. Jy hoef nie vasgevang te bly in kompromieë nie. Jy hoef nie aan te hou om te maak asof alles reg is nie. Jy kan nou dadelik omdraai en God vra om jou skoon te was. Jy kan Hom vra om jou met sy Gees te vul en om die skuldgevoelens en skaamte wat jou vernietig te verwyder en jou vreugde te herstel.Moenie wag nie. Moenie jou skuldgevoelens nog een dag langer dra nie. Jesus het gesterf sodat jy vergewe kan word. Vra God om jou vreugde te herstel en vir jou 'n gees te gee wat gewillig is om Hom te gehoorsaam.Dis God se Woord. Vars... vir jou... vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

Die storie van Josef is 'n voorloper tot die storie van Jesus. Dit vertel van 'n Vader wat verbind is daartoe om Josef se storie te verweef met 'n veel groter narratief: om lewe te skep uit dood. Ons deelname vra vir die geloof en vertroue dat dít God se hart is vir ons ook; dat dít is wat Hy steeds doen. Hy is die tipe outeur wat elke hoofstuk van ons lewens wil verweef tot 'n storie wat lewegend is. Ek dink dis die konteks waarbinne ons Jesus se woorde in Joh 10 moet verstaan: “…Ek het gekom sodat hulle die lewe kan hê, en dit in oorvloed.” – André Luister hier na die klankopname of op die potgooi-platform van jou keuse. . . Of kyk hier saam:

Wie is Jahwe, en wat beteken dié Naam van God vir jou lewe vandag?In hierdie verkorte boodskap ontdek ons Jahwe as die God wat heers, vrede bring, voorsien en genees. Ons kyk na vier betekenisvolle Name waardeur God Homself aan ons openbaar:------------------------------------------------------------------------------------------------------------------TIMESTAMPS0:00 Intro13:41 Jahwe-Sabaot – die Here wat oor alle magte heers19:12 Jahwe-Shalom – die Here wat vrede gee24:21 Jahwe-Jireh – die Here wat voorsien30:06 Jahwe-Rapha – die Here wat genees en herstel------------------------------------------------------------------------------------------------------------------Wat jy ook al vandag in die gesig staar, God se Naam herinner jou aan wie Hy is—en dat jy Hom kan vertrou.Hierdie boodskap vorm deel van ons reeks: Die Name van God.Teken in op ons kanaal vir meer preke en geloofsbemoediging, en deel gerus hierdie boodskap met iemand wat dit vandag nodig het.#Jahwe #DieNameVanGod #AfrikaansePreek #Geloof #TygerbergGesinskerk

"A good way of thinking about this is this is the survival of the fittest clone. There could be a portion of a cancer that naturally has some resistance or ability to survive a particular drug. And over time, as the other cells around it are dying off, that particular clone is able to replicate and continue to survive in the face of that drug therapy and eventually take over as being the fittest clone. At that point, we're often seeing disease progression," Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about resistance pathways.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD), including 30 minutes of pharmacotherapeutic content, by listening to the full recording and completing an evaluation at courses.ons.org by August 7, 2027. Roman has served on advisory boards for Genetech, Pfizer, Regeneron, and Daiichi Sankyo and received honoraria payments from Pharmacy Times and Decera for faculty lectures. These financial relationships have been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge related to resistance pathways in oncology care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 423: Pharmacology 101: Interaction Pathways Episode 406: Drug Resistance Biomarkers and Their Impact on Cancer Treatment Choices ONS Voice articles: Predictive and Diagnostic Biomarkers Scientists Identify Protein Implicated in Tumor Growth, Treatment Resistance ONS book: Guide to Cancer Immunotherapy (second edition) Genomics and Precision Oncology Learning Library ONS Biomarker Database Pharmacogenomics Huddle Card CancerQuest: Cancer Drug Resistance National Comprehensive Cancer Network OncoKB.org Research To Practice To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "As we look at drug resistance, this is the concept that cancer cells are no longer able to respond to a cancer treatment. The downstream of this is that we could end up with progression of the disease and need to look at alternative therapies that may be beneficial for the patient. This is unfortunately a very common phenomenon. Drug resistance is a major cause of treatment failure and poor patient outcomes with treatments. Unfortunately, this is an issue we see that increases over time on treatment." TS 2:29 "Genetics play a really big role in drug resistance. We know that drug resistance can be due to different things. It could be epigenetics. It could be the tumor microenvironment factors. But genetics often play a very big role in resistance pathways. It's generally considered to be a critical contributor to resistance, particularly in the way of acquired variants to drug targets or amplifications of certain oncogenes that can lead cancers to have progression. A well-known genetic alteration is the BRCA1/BRCA2 variant that helps to make the cancer more efficient at fixing DNA damage. So we're trying to get DNA damage with chemotherapy, and this particular variant helps at fixing that damage to allow the cancer to progress. So that is one genetic variant we see that plays a big role in a number of different cancers." TS 4:51 "These pathways are not mutually exclusive. Oftentimes we have multiple resistance pathways involved. I think it's important to understand some of those individually, but kind of thinking about this as we might be facing multiple resistance pathways. ... We can see resistance mechanisms that vary based on the type of treatment we use, for example, traditional cytotoxic chemotherapy. We may be more likely to see some resistance mechanisms that are working at DNA: repairing broken DNA or working on those efflux pumps that are being used to push chemotherapy out of cells. If we're talking more about the targeted therapies such as tyrosine kinase inhibitors or monoclonal antibodies, we may be more likely to see resistance mechanisms that are what we discussed with that drug target alteration: changing the way that the target agents are able to bind to the tumor cells to activate or inactivate pathways so we may see some changes there." TS 12:39 "One way to overcome this and to help to decrease the resistance from developing is using combination therapy: drugs that are targeting different pathways at once or potentially using combinations with things like chemotherapy in addition to immunotherapy. In this way, as we're getting these different targets, we can hopefully decrease the mechanism of resistance that may be developing." TS 14:48 "Biomarker testing is an incredibly important part of our practice. In many situations now, we are getting upfront, comprehensive biomarker testing to identify whether the patient may have any of those intrinsic or primary resistance mechanisms that might make it so a patient is never going to respond to a particular type of treatment. And in that case, we can spare the patient from the potential toxicities of that treatment if we don't think that there's going to be benefit there. So I think that that has become a really important way that we can tailor patients for understanding what treatments are going to be more effective. And then after that, there's usually additional biomarker testing that may be warranted at the time of progression in certain types of cancer. And that really helps us to understand that acquired resistance that might be developing." TS 17:32 "Nurses are really helpful with filling in the gaps and bringing back patient concerns that might be shared with them. And these might be early signs of progression. Better understanding how our patients are feeling and what's going on with them may help us to identify a patient that we need to do some additional testing for to understand whether there is drug resistance ongoing and potential progression of disease." TS 21:52

Ons bid vir een oplossing en God gee ʼn ander een.

Dit is nie maklik om te sê die gaan goed of sleg met die ekonomie nie. Die ekonomie het baie dele. Ons weet dat die reele inkomste van middelklas verbruikers is onder druk.Die afgelope week was daar nuus wat wys dat vervaardiging steeds swaar trek en die landbou-sektor staar uitdagings in die gesig.

7 Augustus 2026: Kiesers kan nog tot middernag aanlyn registreer. Ons praat met die OVK oor die proklamasie van die verkiesingsdatum. Kommer oor e-taxis se veiligheid nadat 'n vrou ontvoer is. Reën en sneeu van Sondag af oor groot dele van die land.

This week we had the privilege of hosting Leif Johan Sevland, President and CEO of the Offshore Northern Seas Foundation (ONS), for a Special Edition. Leif is a Norwegian business leader and former politician with a distinguished career spanning public service and the energy sector. Prior to joining ONS, Leif served as the Mayor of Stavanger from 2005 to 2011. The ONS 2026 Conference is fast approaching, taking place from August 24–27 in Stavanger, Norway. The conference is held biennially and attracts 70,000+ global industry leaders representing over 1,100 companies and 35+ countries. We were honored to host Leif to preview this year's conference, its major themes, and the trends shaping Norway's, Europe's and the world's energy landscape. In our conversation, Leif shared a preview of what attendees can expect at ONS 2026 and how this year's conference theme, Courage, is intended to challenge industry leaders to move beyond discussion and embrace decisive action in addressing the world's evolving energy needs. We explore Norway's unique position as both a leading oil and gas producer and an energy innovator, discussing how energy security, affordability, technological innovation, and shifting geopolitical dynamics are reshaping energy markets, investment priorities, and policy around the world. We examine Europe's evolving innovation ecosystem, the accelerating adoption of AI and its growing impact on power demand, renewed interest in nuclear energy, and the convergence of energy, defense, and industrial technologies. Leif emphasizes the importance of open dialogue, global collaboration, and developing the next generation of industry leaders, and shares how ONS brings together policymakers, operators, investors, entrepreneurs, and innovators to exchange ideas and help shape the future of energy. The Veriten team will be at ONS, participating in a few panels, and connecting with good friends and with some of our partner and portfolio companies that will also be in attendance. Mike Bradley started off the discussion by noting that two key market themes remained in place: lower oil prices and stronger equity markets. The 10-year Treasury yield remained range-bound, showing little directional movement. On the equity market front, the Dow Jones Industrial Average was up ~500 to 600 points on the day, with gains driven primarily by Amgen, Caterpillar, and Goldman Sachs. On the oil market front, downward pressure on crude prices continued, with WTI falling by approximately $1/bbl to around $75/bbl. The decline was driven largely by market optimism that the temporary pause in U.S. military strikes on Iran would remain in place. He noted, however, that oil prices appear increasingly oversold from a technical perspective, having declined roughly $10 to $15/bbl over the past one to two weeks. As a result, crude prices could rebound sharply should the current military pause end or geopolitical tensions re-escalate. He concluded by highlighting key takeaways from Saudi Aramco's 2Q earnings call, noting that management delivered a decidedly bullish message on the outlook for global oil markets. According to Aramco, oil markets are far tighter than many indicators/prices suggest. Aramco noted that global markets lost ~11mmbpd of supply because of the conflict and shipping disruptions; strategic reserve releases and inventory drawdowns have masked the true extent of the shortage; inventory data understates physical market tightness; global inventories have been heavily depleted and must now be rebuilt over several years; and it would take around 18 months and roughly 2.1mmbpd of incremental demand just to restore inventories to pre-conflict levels if conditions normalize immediately. We were fortunate to also have Veriten Venture Partner Karl Liapunov join and share his insights throughout the discussion. Karl is the founder of Starting Cold and is the U.S. Ecosystem Partner at Startuplab, where he previously served as Head of Energy & Climate Tech in Oslo.

Send us Fan MailJakobus 3:13 Is daar 'n wyse en verstandige mens onder julle? Dan moet hy dit toon deur sy goeie gedrag en deur dade wat van nederigheid en wysheid getuig. Dis vreeslik maklik om met groot woorde of intelligente argumente slim te probeer klink. Maar ware wysheid gaan nie oor wat jy sê nie; dit gaan oor hoe jy leef. Ek was self nog altyd vinnig met 'n slim antwoord. Dit kan soms werk, maar dit kan ook vinnig arrogant en lelik oorkom. God moes al baie aan my werk om my te leer om sagter te wees en meer deernis te hê – en hy is nog steeds besig met my. Ja, my vriend, wysheid is baie meer as om bloot net slim te wees.Jakobus 3:13 sê: Is daar 'n wyse en verstandige mens onder julle? Dan moet hy dit toon deur sy goeie gedrag en deur dade wat van nederigheid en wysheid getuig.Die wêreld dink dalk wysheid gaan oor 'n hoë IK, sukses of invloed. Maar vir God lê ware wysheid in hoe jy leef: met 'n sagte hart en opregte nederigheid.Ons grootste voorbeeld van ware wysheid sien ons by Jesus. Hy het nie met 'n swaard en geweld Jerusalem binnegestorm om mense te oorheers nie; hy het nederig op 'n donkie die stad ingery. Hy het nie sy vyande vernietig nie, maar sy lewe vir hulle afgelê. In daardie nederigheid het hy vir ons gewys wat ware wysheid is – die wysheid van die kruis.So, as jy wil weet of jy regtig wys is, moenie kyk na hoe slim jy dink jy is nie. Kyk eerder na hoe nederig jy leef – want ware wysheid is altyd sagmoedig en ware wysheid lyk altyd soos Jesus.Dis God se Woord. Vars … vir jou … vandag.Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

5 Augustus 2026: Die president van die MK-party, Jacob Zuma, kondig ingrypende veranderinge in sy leierstruktuur aan. Hoekom presteer sommige munisipaliteite soveel beter as ander? Ons praat met die FW de Klerk-stigting oor hulle rapport vir plaaslike regerings. Alles wat jy moet weet oor die nuwe 10 jaar-rybewys.

4 Augustus 2026: Ons bespreek die groot gemors waarin die Departement van Militêre Veterane hom bevind, en bring terugvoer op luisteraars se vrae. Kritiek teen die lankverwagte Nasionale Raad teen Geslagsgeweld en Vrouemoord. Die OVK is veral tevrede met die aantal jongmense wat registreer vir die verkiesing.

Is die aarde soos 'n organisme wat homself doelgerig onderhou of is dit hippie nonsens? Ons laat die kletsbots dit uitbaklei.Nog BotBoks episodes: Magalies - KletsBotBoksHoofstukke:00:00; Gaia ying-yang & debat opstel11:05; Die debat begin28:22; Nuwe KI gedrag!39:14; Wat sê Gemini?

Zonder handjes en slimme koppen valt de energietransitie stil. In deze zomeraflevering gaat Harm in gesprek met Wieger Droogh, bestuursvoorzitter van Equans.Ons land is aan het verduurzamen. Tegelijk moeten huizen warm blijven, bedrijven kunnen draaien en het stroomnet overeind blijven. Met 5.500 medewerkers werkt zijn organisatie dagelijks aan die enorme verbouwing van Nederland. Van warmtenetten en energieopslag tot netcongestie en waterstof: Equans zit midden in de technische puzzel van de energietransitie. Hoe groot is het tekort aan vakmensen werkelijk? Waneer hebben we de problemen met het stroomnet opgelost? En heeft hij eigenlijk nog vertrouwen in de klimaatambities van ons land?Deze hele zomer praat Harm in dit programma met mensen die werken aan een betere wereld. Groener, houdbaarder en mooier. We hebben het over de grote, maatschappelijke vragen die spelen bij de transitie naar een volhoudbare toekomst.See omnystudio.com/listener for privacy information.

Send us Fan MailDeuteronomium 13:4 Volg maar net die Here jou God en eer Hom. Gehoorsaam sy gebooie, luister na sy stem en hou vas aan Hom. (NLV) Ek wens ek kon vir jou sê dat die lewe eenvoudig is. Maar dit is nie. Dis kompleks, dis chaoties, en die toekoms is allesbehalwe seker. Jy kan nie eers seker wees van môre of die volgende dag nie! Al wat ons het, is vandag. So, wat gaan jy daarmee doen?'n Paar jaar gelede het 'n navorsingspan ‘n aantal stappers, wat nie kompasse of GPS'e gehad het nie, in digte woude gevolg. Dit was merkwaardig dat byna elkeen van hulle in sirkels geloop het. Dis wat gebeur wanneer ons nie 'n vaste verwysingspunt het nie. Ons verloor almal ons pad – dit maak nie saak hoe hard ons probeer om reguit te loop nie.In hierdie onseker, komplekse en deurmekaar lewe is dit onmoontlik om op koers te bly as jy nie vir God as daardie lewensbelangrike verwysingspunt het nie. Deuteronomium 13:4 Volg maar net die Here jou God en eer Hom. Gehoorsaam sy gebooie, luister na sy stem en hou vas aan Hom. (NLV)Dit is nie ingewikkeld nie. Dis redelik eenvoudig. Dink aan die Israeliete wat op die punt was om 'n land vol afgode en heidene binne te gaan. God se opdrag aan hulle was eenvoudig: Moet nie afdwaal nie. Moet nie in sirkels rondloop nie. Hou julle oë op My.En kyk hoe eenvoudig is Jesus se opdrag: "Volg My." Nie onverskillig nie, nie passief en koud nie - maar met jou hele hart. Hy vra nie net vir ons Sondagoggende nie. Hy vra vir ons lewens.En hier is die goeie nuus. Ons hoef Hom nie in ons eie krag te volg nie. Dieselfde Gees wat Jesus uit die dood opgewek het, lei ons nou, bemagtig ons en hou ons op koers.So as jy afgedwaal het, draai om. Draai vinnig. Fokus jou oë weer op Jesus. Want net ín Hom sal jy reguit en gefokus kan loop.Dit is God se Woord. Vars ... Vir jou... Vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

"When people with PTSD [post-traumatic stress disorder] get quite avoidant—and that can be expressed in so many different ways—the implications can be really profound. I think an important invitation to oncologists and oncology nurses and primary care providers who care for people battling cancer is let's explore what's underneath these avoidant behaviors. Is it a very practical thing? Or is it that underneath this avoidant behavior is really profound fear?" James C. Jackson, PsyD, research professor at Vanderbilt University Medical Center in Nashville, TN, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about addressing medical trauma in oncology. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 31, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to medical trauma in oncology care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 421: Medical Trauma in Oncology Episode 287: Tools, Techniques, and Real-World Examples for Difficult Conversations in Cancer Care Episode 264: Stop the Stressors and Improve Your Mental Health as a Nurse ONS Voice articles: Help Caregivers Control the Chronic Stress of Cancer Care and Manage PTSD [post-traumatic stress disorder] Past Trauma Lowers Hope, QOL, and Coping Ability During Cancer Managing Cancer-Related PTSD Starts With Acknowledgement Moral Injury and Trauma in Nursing Trauma-Informed Care Provides Person-Centered Support for Patients During Deep Distress Clinical Journal of Oncology Nursing articles: How Can a Trauma-Informed Care Approach Be Applied to Patients With Gynecologic Cancer? Psychosocial Barriers to Care: Recognizing and Responding Through a Trauma-Informed Care Approach Oncology Nursing Forum articles: Post-Traumatic Distress and Symptom Experience in Patients With Head and Neck Cancer–Related Tracheostomy and Family Caregivers The Effect of Neuroticism, Fear of Progression, and Self-Efficacy on Post-Traumatic Growth in Patients With Lung Cancer Undergoing Chemotherapy The Relationship Between Colorectal Cancer Survivors' Positive Psychology, Symptom Characteristics, and Prior Trauma During Acute Cancer Survivorship ONS course: Psychosocial Dimensions of Cancer Care™ ONS Huddle Card: Coping Screening tools Clinician-Administered PTSD Scale for DSM-5 [Diagnostic and Statistical Manual of Mental Disorders, 5th edition] (CAPS-5) Hospital Anxiety and Depression Scale Primary Care PTSD Screen for DSM-5 PTSD Checklist for DSM-5 Trauma Screening Questionnaire International Society for Traumatic Stress Studies: Free Resources PESI Reclaiming Your Life From Medical Trauma by James C. Jackson To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "For many people who have been traumatized, if they can avoid it, they will. They may not avoid the annual evaluation that is so hugely consequential—they might not avoid that. But they may well avoid a routine visit for a checkup to their oncologist. They very well may avoid a visit with a psychologist who is wanting them to talk about hard things. They may avoid visiting a friend in the hospital because it reminds them of really upsetting things. So, this issue of adherence and compliance is a really big problem." TS 3:19 "Screening tools for things like PTSD can be very useful. They're quite practical, and they're appropriate to use. I really like something called the Post-Traumatic Stress Disorder Checklist. ... Using it is going to be very straightforward. You're going to want to map it onto a 30-day window, and you're going to employ it with patients. It's a 20-item self-report. It assesses 20 DSM-5 symptoms of PTSD. It's not diagnostic, but if people score in this range of 30, 31, 33, we typically are going to believe that that is very suggestive of significant PTSD." TS 9:17 "One of the things we should be doing all the time is modeling and attempting to normalize this idea of being open about mental health difficulties. When I say modeling, this is a complicated issue. ... I'm very open talking about my own battles with mental health. And in some ways, that invites my patients to do the same. I don't recommend necessarily that a nurse says, 'Oh, by the way, I have PTSD. I'm going to tell you about mine. I want you to tell me about yours.' That's a boundary issue. But I think it does behoove us as clinicians to create a culture as much as we're able, where we can talk about mental health difficulties in a matter-of-fact way, acknowledging that mental health is health. These tools, to me, go a long way in that direction." TS 13:41 "The survivorship process is ongoing. I think a nurse can assist a patient in so many ways longitudinally over time. ... One of those ways is to continue checking on mental health outcomes in patients. Continuing to check on mental health outcomes, continuing to explore them, and continuing to invite patients to talk about things that other people might not be asking about. It's easy for family members to assume, 'Hey, you know, you're cancer free now. You look fine, so you must be fine.' It's very possible that the patients we're talking about are not fine. They're far from fine. For that oncology nurse at a follow-up clinic or in an oncology setting to talk about this, continuing to affirm that it would be okay for patients to struggle, continuing to put this issue on a front burner—I think that's really important." TS 21:17 "I'm aware of nurse-led support groups where nurses can talk very freely about their own challenges, in a safe space. ... Working to build cultures in the context of the intensive care unit, let's say, where we have a lot of patients with cancer that prioritize well-being nurse driven programs. ...  The bottom line is if there is a warning light that is blinking, nurses need to attend to that. And in attending to it, they're going to be more present for their patient. They're going to be better able to support their patient. They're going to be better able to support each other. And I think often, in the culture of nursing and psychology, too, people just put their head down, their shoulder down, and they just plow through in ways that are really counter to their mental health." TS 29:56 "The truth is medical trauma can be well-managed. It's not simple. It's not always intuitive. There are all sorts of caveats with regard to this, but the truth is people with medical trauma can live really rich and meaningful lives. ... So, the default setting, I think, should be not one of pessimism. It should be that people with medical trauma can and do get better. If you are a patient with medical trauma and you are in my purview, until proven differently, I'm going to assume that you can get better too." TS 36:28

"In oncology specifically, where care is complex, artificial intelligence (AI) can really synthesize large volumes of clinical information, flag risks such as treatment complications, and support adherence to evidence-based pathways. For nurses specifically, this enables them more time for direct patient care, clinical judgment, and care coordination, and really practice to the top of their license while reducing repetitive time and administrative tasks," Jenn Frith, DNP, RN, OCN®, NE-BC, associate vice president of clinical operations at Duke Cancer Institute in Durham, NC, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS. Weimer spoke with Frith and Emily Norboge, director of clinical and research informatics at Duke Cancer Institute, about how AI can help healthcare organizations improve the cancer experience.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 24, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the use of artificial intelligence in oncology nursing practice. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 284: How AI Is Influencing Cancer Care and Oncology Nursing Episode 281: Nursing's Role in AI in Health Care ONS Voice articles: Human Connection Creates the Power Behind AI in Nursing If You're Using AI in Health Care, Your Patients Want to Know Majority of Adults Use AI, But Most Distrust Accuracy of Health Information Nurses Are Key to Quality for AI Tools in Oncology Care One-Third of Hospitals Have Integrated Generative AI Into EHRs, With More to Follow Clinical Journal of Oncology Nursing articles: A Case for Caution: Patient Use of Artificial Intelligence Artificial Intelligence in Oncology Nursing: Preparing the Workforce for the Future Artificial Intelligence: Basics, Impact, and How Nurses Can Contribute Integrating Artificial Intelligence Into Cancer Care: Enhancing Nursing Practice and Bridging Disparities Oncology Nursing Forum article: Artificial Intelligence for Oncology Nursing Authors: Potential Utility and Concerns About Large Language Model Chatbots To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Norboge: "Our AI voice agent has a series of workflows that it can execute. ... If a patient needs help with medical paperwork, the agent will walk the patient through how to do that paperwork. If a patient has a question that they need sent to their provider, it can document that and then send a message to the provider. There's a series of workflows so it can route to scheduling. It can answer information about test results that is compliant with our policy around test results. The goal of that agent is that it will handle all of those administrative-type tasks that don't necessarily require a nurse to fill." TS 5:44 Norboge: "When [patients] call the nurse triage line, the nurse will have to say, 'I understand you want your test results. I can contact your provider and have them reach out to you about your results.' But that's kind of where it ends. What we worked out with the agent is if a patient calls and says, 'I really want my test results,' they will in a very nice, standard way, say something similar. You know, 'I'm not authorized to discuss your test results with you, but I'd be happy to send a message to your provider and ask them to call you.' But then the agent goes one step further and says, 'Are you experiencing anxiety about your test results? If so, I can transfer you to the nurse to discuss support for a potential referral to family medical therapy if you would like help managing that anxiety.' In a clear, helpful way, it can define and help a patient with their needs and not just have a standard of 'this is our policy and I can't share it with you.'" TS 11:14 Frith: "Really, transparency is the key. The patient should understand that AI is used more as an enhancement, but not to replace the human connection. That's not the goal. The nurses can explain that the tools will help ensure accuracy, timeliness, and safety while allowing more time for the direct interaction of the nurse. I think framing AI as an additional layer of support rather than a decision maker helps build trust. And I think maintaining strong communication and presence at the bedside just reinforces that care remains fundamentally human." TS 15:32 Frith: "I think AI in oncology is going to continue to advance in our predictive analytics, personal care planning, and probably real-time decision support. I think we'll see a greater integration into symptom management, some early detection of complications, and longitudinal care coordination across our settings. I think nurses will continue to increasingly use AI to anticipate patient needs and prioritize care. I think the role of the nurse won't diminish. Rather, it will become more elevated in allowing them to practice to scope of practice." TS 19:58 Frith: "AI represents a meaningful opportunity to strengthen oncology nursing practice by reducing burden and enhancing the clinical insight. It needs to be a very thoughtful implementation. We talked about having strong governance and continued investment in the nursing workforce. I want to reinforce that oncology care remains deeply human, and AI should only be viewed as a tool that enables the nurses to do what they do best, which I feel is deliver safe, compassionate, and high-quality specialized care to our most vulnerable patients." TS 27:31

Vandaag in De 7: Ons land krijgt er in een klap een Europese marktleider bij in logistiek vastgoed. Het Belgische WDP neemt zijn Franse sectorgenoot Argan over. Telecomspelers Proximus en Telenet gaan samen glasvezel uitrollen in Vlaanderen. Maar dat zijn concurrenten, dus wat houdt die deal precies in? Komende nacht doven de algemene Amerikaanse invoertarieven van 10 procent normaal gezien uit. Maar president Trump lanceert meteen alweer een nieuw salvo. Hoe lang gaat hij die estafette nog volhouden? Host: Roan Van EyckProductie: Lore AllegaertSee omnystudio.com/listener for privacy information.

Become a part of the Progressive Property refer-a-friend scheme and Earn up to £250 when someone attends one of our events – you can enrol here: https://www.progressiveproperty.co.uk/raf/ Right now, in 2026, thousands of landlords are quietly dumping perfectly good properties because a journalist told them - “UK rents have cooled to 3%.” They're reading a single national average as if it were a buy or sell signal. In the process, sleep‑walking past the best buying conditions they've seen in years.   In this episode, Mark shows why that headline is technically true but practically useless if you're deploying capital. He walks through the real ONS and Rightmove data, explains how London has smashed into an affordability ceiling while the Northeast and Midlands still have headroom, and reveals why asking prices can rise even as real values soften. More importantly, he lays out how sophisticated investors are quietly stepping into those nearly 6% rent inflation regions, structuring around stamp duty, and using inflation to devalue their debt while amateur landlords run for the exits. If you want to take the next step and put what you have learned from this podcast into action, you only need to click here - https://www.wealthbuilders.co.uk/progressive-podcast KEY TAKEAWAYS National averages are a terrible way for investors to assess whether it is time to buy or not.  London has hit an affordability ceiling, while the Midlands and Northeast still have wage headroom and rising rents.  Smart investors are ignoring the national mood and targeting specific streets in high‑yield regions. Amateur landlords are panic‑selling in the very regions where tighter supply is likely to push rents higher.  At a time when yields and inflation are quietly working in favour of buyers.   BEST MOMENTS  “The headline isn't wrong, it's just useless.”   “Because of that one headline, landlords across the country are panic selling perfectly good properties this month.” “The market isn't dying. The heat is migrating.” “Navigating this market based on headlines is a massive risk in the current economic climate.”   If you want a complete circuit breaker from the media noise, join Mark's Multiple Streams of Property Income training that works regardless of market conditions. Bring your deals, your doubts, and your spreadsheets, and walk out with a strategy built to work in today´s market, not the one in the headlines. Spots are limited, so grab yours here: https://progressiveproperty.co.uk/msopi/ VALUABLE RESOURCES MSOPI – Multiple Streams of Income: https://www.progressiveproperty.co.uk https://kevinmcdonnell.co.uk ABOUT THE HOST Sean Fitzpatrick is a property investor, educator, and the Face of Progressive Property. With a 6-figure portfolio and expertise in creative strategies, finance, and off-market deals, Sean shares success stories from the Progressive Property community, expert insights, and real-world strategies to help investors succeed. Tune in for practical tips and no-nonsense advice to accelerate your property journey. ABOUT THE HOST Kevin McDonnell is a Speaker, Author, Mentor & Professional Property Investor. He is an expert when it comes to creative property investment strategies. His book No Money Down: Property Invest talks about how to control and cash flow other people's property to create financial freedom.   CONTACT METHOD https://www.facebook.com/kevinMcDonnellProperty https://kevinmcdonnell.co.uk TikTok: https://www.tiktok.com/@progressiveproperty YouTube: https://www.youtube.com/channel/UC0g1KuusONVStjY_XjdXy6g Twitter: https://twitter.com/progperty LinkedIn: https://www.linkedin.com/company/progressiveproperty Instagram: https://www.instagram.com/progressiveproperty Facebook Community: https://www.facebook.com/groups/progressivepropertycommunity Facebook Page: https://www.facebook.com/Progperty This Podcast has been brought to you by Disruptive Media. https://disruptivemedia.co.uk/

"Think about what organs lie in the radiation field, and anything that lies in that radiation field is likely going to have some potential temporary—hopefully temporary—side effects. If you think about the pelvis, the things that live in there are the bladder, urethra, some bowel, rectum, reproductive organs, skin, some lymph nodes. And so, all of those things could potentially have associated side effects," ONS member Kayla Kafka-Peterson, BSN, RN, ROCN™, nurse navigator and leader in the brachytherapy and peri-anesthesia programs at UCLA Health, in Los Angeles, CA, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about radiation side effects in cancers of the pelvis. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 17, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to radiation to the pelvis. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Radiation Site-Specific Side Effects series Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles ONS Voice articles: Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education The Intersection of Pelvic Health and Oncology Optimizes Sexual Symptom Management ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: Nurse Navigation and Care During Brachytherapy for Cervical Cancer: 2025 ONS Bridge™ Session ONS ROCN™ Certification Review™ ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Updated Interventions for Radiation-Induced Diarrhea: Putting Evidence Into Practice With the Oncology Nursing Society Genitourinary Distress: Common Side Effect Sexual Dysfunction: Common Side Effect Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers Oncology Nursing Forum article: Effect of Foot Reflexology and Aromatherapy on Anxiety and Pain During Brachytherapy for Cervical Cancer ONS Guidelines™ and Symptom Management Resources: Radiodermatitis Radiation-Induced Diarrhea Brachytherapy Huddle Card American Brachytherapy Society American Society for Radiation Oncology (ASTRO) European Society for Radiotherapy and Oncology (ESTRO) GEC-ESTRO Committee International Gynecologic Cancer Society Nursing Certificate Program To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Brachytherapy is delivered two main ways. The most common is LDR and HDR. LDR stands for low-dose-rate radiation, which is the older type of brachytherapy, but it is still very much practiced today. And it is where we put radioactive seeds directly into the tumor or tumor resection bed, depending on what you're treating. And those pieces of radioactive material, such as iodine-125 or palladium-103, those will give off radiation over time and treat the area that they are in, and they will place more or less seeds into the tumor, depending on that patient's needs and their anatomy." TS 3:26 "The most common [side effect] for external beam is bladder irritation—cystitis. It can be some burning, some frequency, some urgency, and it can often mimic a UTI [urinary tract infection]. We also have to make sure our patients do not have a UTI. Most of the time they don't, but we don't want to miss that. Once a UTI has been ruled out, the mucosa in the bladder and the urethra, it has a very high cell turnover rate. And things with a high cellular turnover rate like mucosal linings, they respond to radiation very quickly. They also heal very quickly, but they start to break down quite quickly during radiation." TS 16:15 "For the bladder, some things that we can teach the patients … to keep their urinary system as comfortable as possible during treatment. We really encourage hydration because the more hydrated they are, the more diluted their urine will be and the less acidic it will be. As those tissues start to respond to the radiation, they will become, for lack of a better word, a little bit raw. And if you think of something acidic going on something that is raw, it's going to burn, and these patients do get burning. And so by promoting hydration, their urine becomes less acidic; it doesn't burn as much when they do urinate. And I find a lot of patients who are experiencing the urinary side effects, they don't want to drink because they're afraid to urinate. And it actually makes the burning worse because their urine gets ultra-concentrated." TS 22:29 "Anybody who has a vagina, who receives treatment to the pelvis—it doesn't matter if it's for vaginal cancer or if it's for bowel or rectal—if they have received radiation to the pelvis, they are at risk for vaginal stenosis and adhesions. And this, of course, can be more pronounced in patients who have a higher dose in the vagina or a larger surface volume of the vagina treated. But over time, that tissue, even long after radiation is done, will undergo late changes where they will have continued scar formation, and it starts to lose its elasticity and its functionality. And at times it can stick to itself, causing these adhesions." TS 28:15 "I think a common misconception is that you cannot safely work around radiation. That is something that I have heard a lot. In certain regions of the world, the nurses actually report that they have been having trouble getting good applicants because nobody wants to work in radiation because they think that you'll get radiated, that it's not safe. We've really tried to make radiation safety a big part of our teaching to show that actually, you can safely work around radiation with today's technology." TS 41:43

15 Julie 2026: Konsepwetgewing vir 'n enkele, onafhanklike regterlike gesag sal vroeg aanstaande jaar gereed wees. President Cyril Ramaphosa gaan vandag hof toe om die werksaamhede van die afsettingskommittee oor die Phala Phala-aangeleentheid te stop. Ons kyk na wat die Madlanga-kommissie se koste uiteindelik kan beloop, en vra of dit finansieel die moeite werd is.

Hoe reageer je als een dakloos persoon je om wat kleingeld vraagt? Maak je een praatje, geef je een euro, of loop je door terwijl je gebaart dat je haast hebt? En waarom maak je die keuze eigenlijk op dat moment? Daklozen krijgen te maken met sterke vooroordelen. Maar waarom reageren we eigenlijk zoals we dat doen, en hoe hangt dat samen met de beeldvorming rondom dakloosheid in onze samenleving? Leer van straatarts Maria van den Muysenbergh, psycholoog Gijs Bijlstra en ervaringsdeskundige Miquel Roest over onze ideeën over dakloosheid ontstaan zijn en welke impact dat heeft op de mensen die op straat belanden. Een praatje, een euro, of doorlopen? Ons beeld van dakloosheid | Lezing en gesprek met straatarts Maria van den Muysenbergh, psycholoog Gijs Bijlstra en ervaringsdeskundige Miquel Roest | Maandag 15 juni 2026 | 20.00 – 21.30 uur | LUX , Nijmegen| Radboud Reflects en Stichting Straatmensen voor Straatmensen Bekijk de terugblik: https://www.ru.nl/diensten/sport-cultuur-en-ontspanning/radboud-reflects/nieuws/een-praatje-een-euro-of-doorlopen-ons-beeld-van-dakloosheid-lezing-en-gesprek-met-straatarts-maria-van-den-muysenbergh-psycholoog-gijs-bijlstra-en-ervaringsdeskundige-miquel-roest Like deze podcast en abonneer je op dit kanaal. Bekijk ook de agenda voor nog meer verdiepende lezingen: www.ru.nl/radboudreflects Wil je geen enkele verdiepende lezing missen? Schrijf je dan in voor de nieuwsbrief: www.ru.nl/rr/nieuwsbrief

Inleiding tot les 181-200Ons volgend stel lessen is speciaal gericht op de versteviging van je bereidwilligheid om je zwakke inzet sterk te maken en je uiteenlopende doelstellingen tot één intentie samen te smeden. Er wordt vooralsnog geen voortdurende en totale toewijding van je gevraagd. Maar jou wordt gevraagd nu te oefenen om het gevoel van vrede te bereiken dat een dergelijke volledige inzet, al is het maar met tussenpozen, je zal schenken. Juist de ervaring hiervan garandeert dat jij je totale bereidwilligheid zult inzetten om de weg te volgen die de cursus uiteenzet.Onze lessen zijn nu met name afgestemd op het verruimen van horizonten en op een directe aanpak van de speciale belemmeringen die jouw visie vernauwd hebben en te beperkt houden om jou de waarde van ons doel te laten zien. We doen nu een poging deze belemmeringen op te heffen, hoe kortstondig ook. Woorden alleen kunnen het gevoel van bevrijding waarmee dit gepaard gaat, niet overbrengen. Maar de ervaring van vrijheid en vrede die ontstaat wanneer jij je rigoureuze controle over wat je ziet opgeeft, spreekt voor zich. Jouw motivatie zal zo worden versterkt dat woorden niet meer zo belangrijk zijn. Je zult zeker zijn over wat jij wilt, en over wat geen waarde heeft.En zo beginnen we onze reis die aan woorden voorbijgaat, door ons eerst te concentreren op wat jouw vooruitgang nog steeds in de weg staat. De ervaring van wat voorbij een verdedigende houding ligt, blijft buiten je bereik zolang je het bestaan daarvan ontkent. Het is er misschien, maar je kunt de aanwezigheid ervan niet accepteren. Dus proberen we nu elke dag voor eventjes aan alle verdedigingen voorbij te gaan. Meer wordt er niet gevraagd, want meer is er niet nodig. Het zal voldoende zijn om te garanderen dat de rest zal komen.LES 192Ik heb een functie die God me graag vervullen ziet.Het is je Vaders heilige Wil dat jij Hemzelf compleet maakt, en dat jouw Zelf Zijn heilige Zoon is, voor eeuwig zuiver zoals Hij, uit liefde geschapen en in liefde bewaard, liefde uitbreidend, scheppend in haar naam, voor eeuwig één met God en met jouw Zelf. Maar wat kan zo'n functie betekenen in een wereld vol afgunst, haat en aanval?Daarom heb je een functie in de wereld in haar eigen termen. Want wie kan een taal begrijpen die zijn eenvoudig begrip verre te boven gaat? Vergeving vertegenwoordigt jouw functie hier. Ze is niet Gods schepping, want ze is het middel waarmee onwaarheid ongedaan kan worden gemaakt. En wie zou aan de Hemel vergeving willen schenken? Maar op aarde heb je het middel nodig om illusies los te laten. De schepping wacht louter op jouw terugkeer om te worden erkend, niet om compleet te zijn.Van de schepping valt in deze wereld zelfs geen voorstelling te maken. Ze heeft hier geen betekenis. Vergeving is hetgeen waarmee ze nog het dichtst bij de aarde komen kan. Want in de Hemel ontstaan, heeft ze in het geheel geen vorm. Maar God heeft Iemand geschapen die het vermogen heeft om het totaal vormloze in vorm te vertalen. Wat Hij maakt zijn dromen, maar van een soort zo dicht bij ontwaken, dat het daglicht er al in schijnt, en ogen, die zich al openen, het vreugdevolle schouwspel dat zij bieden aanschouwen.Vergeving beziet mild alles wat onbekend is in de Hemel, ziet het verdwijnen, en laat de wereld achter als een schone, onbeschreven lei waarop het Woord van God de zinloze symbolen die er eerst geschreven stonden, nu vervangen kan. Vergeving is het middel waardoor de angst voor de dood overwonnen wordt, omdat die nu geen hevige aantrekkingskracht meer uitoefent en schuld verdwenen is. Vergeving laat het lichaam zien als wat het is: een eenvoudig leermiddel dat terzijde wordt gelegd wanneer het leren is voltooid, maar hem die leert allerminst verandert.De denkgeest zonder lichaam kan geen vergissingen maken. Hij kan niet denken dat hij sterven zal, of de prooi zal zijn van een genadeloze aanval. Woede wordt onmogelijk en waar blijft dan panische angst? Welke angsten zouden hen nog kunnen bedreigen die de bron van alle aanval, het wezen van leed en de zetel van angst zijn kwijtgeraakt? Alleen vergeving kan de denkgeest ontlasten van de gedachte dat het lichaam zijn thuis is. Alleen vergeving kan de vrede herstellen die God voor Zijn heilige Zoon heeft bestemd. Alleen vergeving kan de Zoon ertoe bewegen weer zijn oog te richten op zijn heiligheid.Wanneer woede verdwenen is, zul je inderdaad ontdekken dat er voor de visie van Christus en de gave van het zien geen offer werd gevraagd, en slechts pijn werd weggenomen van een zieke en gekwelde denkgeest. Is dit onwelkom? Is dit iets om bang voor te zijn? Of is het iets om op te hopen, om dankbaar te begroeten en vol vreugde in ontvangst te nemen? We zijn één en geven daarom niets op. Maar waarlijk is ons alles gegeven door God.Toch hebben we vergeving nodig om te zien dat dit zo is. Zonder haar vriendelijk licht tasten we in het duister rond en gebruiken we ons verstand slechts om onze razernij en aanval te rechtvaardigen. Ons begrip is zo beperkt, dat wat we denken te begrijpen niets anders is dan een uit vergissing voortkomende verwarring. Wij zijn verdwaald in de nevelen van wisselende dromen en angstwekkende gedachten, met onze ogen stijf dichtgeknepen tegen het licht, en onze denkgeest druk bezig met het aanbidden van wat er niet is.Wie kan opnieuw in Christus geboren worden dan hij die ieder die hij ziet, aan wie hij denkt, of die hij zich voorstelt, vergeven heeft? Wie zou bevrijd kunnen worden terwijl hij nog iemand gevangen houdt? Een cipier is niet vrij, want hij zit samen met zijn gevangene vast. Hij moet ervoor zorgen dat die niet ontsnapt en dus brengt hij zijn tijd door met de wacht over hem te houden. De tralies die hem beperken worden de wereld waarin zijn cipier leeft, samen met hem. En van zijn vrijheid hangt de weg naar bevrijding voor hen beiden af.Houd daarom niemand gevangen. Bevrijd in plaats van te binden, want zo word jij bevrijd. De manier is eenvoudig. Telkens wanneer je een steek van woede voelt, besef dan dat je een zwaard boven je eigen hoofd houdt. En het zal vallen of afgewend worden, naargelang je verkiest veroordeeld te worden of vrij te zijn. Op die manier vertegenwoordigt ieder die jou in de verleiding lijkt te brengen om kwaad te worden, jouw verlosser uit de kerker van de dood. En dus ben je hem dank verschuldigd in plaats van pijn.Wees vandaag genadig. De Zoon van God verdient jouw genade. Hij is het die jou vraagt de weg naar de vrijheid nu te aanvaarden. Weiger het hem niet. De Liefde die Zijn Vader hem betoont behoort jou toe. Jouw functie hier op aarde is slechts dat je hem vergeeft, opdat je hem weer als jouw Identiteit aanvaardt. Hij is zoals God hem geschapen heeft. En jij bent wat hij is. Vergeef hem nu zijn zonden en je zult zien dat je één met hem bent.Alle tekst- werk en handboek klassen van Een Cursus in Wonderen met Elbert nu te beluisteren en te bekijken op https://decursusmetelbert.nl

"When we think of drug interactions, specifically, the National Cancer Institute actually defines this as a change in the way a drug acts in the body when taken with certain other drugs, herbals, or foods or when taken with certain medical conditions. Drug interactions may cause the drug to either be more or less effective or cause effects on the body that are not expected," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about interaction pathways. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD), including 30 minutes of pharmacotherapeutic content, by listening to the full recording and completing an evaluation at courses.ons.org by July 10, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge related to drug interactions in oncology care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series ONS Voice articles: Are Your Patients Taking Herbs That May Interact With Their Cancer Drugs? Pharmacogenomics Testing Helps to Ensure That Effective Therapy Is Safe Therapy Use of Herbal Products Carries Risk for Drug Interactions, but Patient–Clinician Knowledge, Communication Remain Low What the Research Says About Drug Interactions and Medical Cannabis ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) ONS Huddle Cards: DPYD Gene and DPD Enzyme Pharmacogenomics ONS Oral Anticancer Medication Toolkit American Journal of Nursing articles: Understanding Pharmacokinetics: Part1: Drug Absorption Understanding Pharmacokinetics: Part 2: Drug Distribution Understanding Pharmacokinetics: Part 3: Drug Metabolism Understanding Pharmacokinetics: Part 4: Drug Elimination Journal of Nuclear Medicine Technology articles: Pharmacology, Part 1: Introduction to Pharmacology and Pharmacodynamics Pharmacology, Part 2: Introduction to Pharmacokinetics ClinPGx To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "One of the most notable food interactions that interacts with many different medications is actually grapefruit or grapefruit juice. This is known to be a very strong CYP3A4 inhibitor. … A lot of medications are metabolized through the CYP3A4 pathway. By inhibiting the effect of these enzymes, that can actually increase and significantly increase the concentrations of these therapies. It's not an interaction that's just limited to grapefruit. I would say grapefruit being in the food interaction is kind of one of the most well-known, but it can also be seen with other foods as well, like pomegranate juice or a very specific type of orange called Seville oranges. And this is really just due to the presence of a substance called furanocoumarins." TS 6:12 "There have been a pretty large number of genes identified that are responsible for coding some of those common enzyme families that I had been discussing, some of those CYP450 enzymes, but other enzymes as well that are important for drug metabolism. Based on the type of gene, there could be some different categories where patients are normal metabolizers, intermediate metabolizers, or poor metabolizers. There are some other categories as well based on the type of gene we're looking at. And that can ultimately impact the way you are able to metabolize drugs." TS 15:56 "Another common [geneotypic variation] that we always think about in oncology is G6PD, where if someone has G6PD deficiency, these patients can be at greater risk of hemolytic anemias when receiving certain types of therapies. Dapsone and rasburicase are just a couple that have been associated with this risk." TS 17:50 "One of the big concerns is always polypharmacy. Our patients truly can be on a lot of medications. In the field that I work in, transplant, patients automatically from their transplant are on many, many different medications that can potentially predispose them to side effects. … But I think when it comes to the many drug interactions that may flag in these situations, we really have to look at the patient as a whole. Like, how long have these patients been on these therapies? Are they having side effects? Have they been on the combination for a very long time now? So I think that not just looking at the drug reference and seeing that there are like 10 different interactions flagged, but really assessing your patient as a whole can be very important—just because real-world practice, of course, is not black and white. It's often very gray, so it's just important to use clinical judgment in those scenarios." TS 26:10

NESTA EDIÇÃO. CNPE se reúne nesta quarta com E32 e moratória das importações de biodiesel na pauta; Departamento de Energia dos EUA reduz projeção para o preço do petróleo para 2026 e 2027 – mas barril volta a subir na terça; ONS divulga lista dos agentes admitidos na 1ª Temporada de Acesso de 2026, que reorganiza fila de acesso de pedidos de conexão de grandes consumidores de energia. ***Locução gerada por IA

7 Julie 2026: Die Menseregtekommissie vra die regering om in te gryp nadat minstens 600 buitelanders in Kaapstad gestrand is. Ons bespreek Ayanda Dlodlo se aanstelling as ambassabeur in Frankryk. Ongeloof oor FIFA se besluit om 'n verbod op 'n Amerikaanse doelskieter op te hef ná 'n telefoonoproep van president Trump - nie dat dit gewerk het nie, want Amerika was gister die laaste gasheerland om die trekpas te kry by die Wêreldbeker-eindtoernooi.

Inleiding tot les 181-200Ons volgend stel lessen is speciaal gericht op de versteviging van je bereidwilligheid om je zwakke inzet sterk te maken en je uiteenlopende doelstellingen tot één intentie samen te smeden. Er wordt vooralsnog geen voortdurende en totale toewijding van je gevraagd. Maar jou wordt gevraagd nu te oefenen om het gevoel van vrede te bereiken dat een dergelijke volledige inzet, al is het maar met tussenpozen, je zal schenken. Juist de ervaring hiervan garandeert dat jij je totale bereidwilligheid zult inzetten om de weg te volgen die de cursus uiteenzet.Onze lessen zijn nu met name afgestemd op het verruimen van horizonten en op een directe aanpak van de speciale belemmeringen die jouw visie vernauwd hebben en te beperkt houden om jou de waarde van ons doel te laten zien. We doen nu een poging deze belemmeringen op te heffen, hoe kortstondig ook. Woorden alleen kunnen het gevoel van bevrijding waarmee dit gepaard gaat, niet overbrengen. Maar de ervaring van vrijheid en vrede die ontstaat wanneer jij je rigoureuze controle over wat je ziet opgeeft, spreekt voor zich. Jouw motivatie zal zo worden versterkt dat woorden niet meer zo belangrijk zijn. Je zult zeker zijn over wat jij wilt, en over wat geen waarde heeft.En zo beginnen we onze reis die aan woorden voorbijgaat, door ons eerst te concentreren op wat jouw vooruitgang nog steeds in de weg staat. De ervaring van wat voorbij een verdedigende houding ligt, blijft buiten je bereik zolang je het bestaan daarvan ontkent. Het is er misschien, maar je kunt de aanwezigheid ervan niet accepteren. Dus proberen we nu elke dag voor eventjes aan alle verdedigingen voorbij te gaan. Meer wordt er niet gevraagd, want meer is er niet nodig. Het zal voldoende zijn om te garanderen dat de rest zal komen.LES 186De verlossing van de wereld hangt af van mij.Dit is de uitspraak die alle arrogantie eens uit elke denkgeest weg zal nemen. Dit is de gedachte van ware nederigheid, die geen andere functie als de jouwe neemt dan degene die jou gegeven is. Het brengt jouw aanvaarding van een jou toegewezen taak met zich mee, zonder aan te dringen op een andere rol. Het velt geen oordeel over de juiste rol voor jou. Het erkent slechts dat de Wil van God op aarde zowel als in de Hemel is geschied. Het verenigt elke wil op aarde in het hemelse plan om de wereld te verlossen en haar terug te voeren tot de hemelse vrede.Laten we onze functie niet bestrijden. Wij hebben die niet vastgesteld. Ze is niet ons idee. De middelen waarmee ze volmaakt zal worden vervuld, zijn ons gegeven. Het enige wat ons wordt gevraagd is dat wij onze taak in oprechte nederigheid aanvaarden en niet met zelfmisleidende arrogantie ontkennen dat we die waardig zijn. Wat ons te doen gegeven is, daartoe hebben we de kracht. Onze denkgeest is volmaakt toegerust om de taak op zich te nemen die ons is toegewezen door Iemand die ons goed kent.Het idee van vandaag lijkt misschien heel ontnuchterend, totdat je de betekenis ervan ziet. Al wat het zegt is dat jouw Vader Zich jou nog steeds herinnert en je het volmaakte vertrouwen schenkt dat Hij in jou heeft als Zijn Zoon. Het vraagt niet dat je op enigerlei wijze anders bent dan jij bent. Wat zou nederigheid anders kunnen vragen dan dit? En wat zou arrogantie anders kunnen weigeren dan dit? Vandaag zullen we ons niet aan onze opdracht onttrekken met de schoonschijnende reden dat bescheidenheid geweld wordt aangedaan. Het is trots om de Roep namens God Zelf te willen ontkennen.Alle valse nederigheid leggen we vandaag naast ons neer, zodat we kunnen luisteren naar Gods Stem, die ons onthult wat Hij ons wil laten doen. We twijfelen niet aan onze geschiktheid voor de functie die Hij ons aanbieden zal. We zijn er alleen zeker van dat Hij onze krachten, onze wijsheid en onze heiligheid kent. En als Hij ons waardig acht, dan zijn we dat. Het is slechts arrogantie om er anders over te oordelen.Er is één manier, en slechts één, om te worden bevrijd uit de gevangenschap die jouw plan om te bewijzen dat het onware waar is, jou heeft gebracht. Accepteer in plaats daarvan het plan dat jij niet hebt gemaakt. Oordeel niet over jouw waarde daarvoor. Als Gods Stem jou verzekert dat de verlossing jouw aandeel nodig heeft en dat het grote geheel van jou afhankelijk is, wees er dan zeker van dat dit zo is. De hoogmoedigen moeten zich wel vastklampen aan woorden, bang als ze zijn die te overstijgen en iets te ervaren wat hun standpunt zou kunnen tarten. Maar de nederigen zijn vrij om de Stem te horen die hun zegt wat ze zijn en wat hun te doen staat.Arrogantie maakt een beeld van jezelf dat niet werkelijk is. Het is dit beeld dat huivert en in doodsangst terugdeinst wanneer de Stem namens God jou verzekert dat jij de kracht, de wijsheid en de heiligheid bezit om alle beelden te overstijgen. Jij bent niet zwak, zoals het beeld van jezelf dat is. Jij bent niet onwetend en hulpeloos. Zonde kan de waarheid in jou niet bezoedelen en ellende kan niet dichtbij Gods heilige woning komen.Dit alles verkondigt jou de Stem namens God. En terwijl Hij spreekt, siddert het beeld en probeert het de bedreiging die het niet kent aan te vallen, terwijl het zijn fundament voelt afbrokkelen. Laat het los. De verlossing van de wereld hangt af van jou en niet van dit hoopje stof. Wat kan het de heilige Zoon van God vertellen? Waarom zou hij er zich überhaupt om bekommeren?En zo vinden we onze vrede. We zullen de functie aanvaarden die God ons gegeven heeft, want alle illusies berusten op de eigenaardige overtuiging dat we voor onszelf een andere kunnen maken. Onze eigengemaakte rollen zijn wisselend en lijken te variëren van rouwdrager tot de extatische gelukzaligheid van liefde en liefhebben. We kunnen lachen of huilen, en de dag begroeten met open armen of met tranen. Ons diepste wezen schijnt te veranderen wanneer we duizend stemmingswisselingen ervaren en onze emoties ons hoog verheffen, of ons in wanhoop neersmakken op de grond.Is dit de Zoon van God? Zou Hij zo'n instabiliteit kunnen scheppen en dat Zoon noemen? Hij die onveranderlijk is deelt Zijn eigenschappen met Zijn schepping. Alle beelden die Zijn Zoon lijkt te maken, hebben geen effect op wat hij is. Ze dwarrelen door zijn denkgeest als door de wind opgewaaide bladeren die een ogenblik een patroon vormen, uit elkaar vallen, zich hergroeperen en wegvliegen. Of als luchtspiegelingen die boven een woestijn worden gezien, oprijzend uit het stof.Deze schimmige beelden zullen verdwijnen en je denkgeest onbeneveld en sereen achterlaten, wanneer jij de functie accepteert die jou gegeven is. De beelden die je maakt laten alleen tegenstrijdige doelen ontstaan die vergankelijk en vaag, onzeker en meerduidig zijn. Wie zou standvastig in zijn pogingen kunnen zijn, en zijn energie en geconcentreerde volharding op zulke doelen kunnen richten? De functies die de wereld hoogacht, zijn zo onzeker dat ze op hun zekerst minstens tien keer per uur veranderen. Welke hoop is er dat er bij zulke doelen iets kan worden gewonnen?In liefdevolle tegenstelling daarmee onderscheidt zich, zo zeker als de zon elke morgen terugkeert om de nacht te verjagen, helder en geheel ondubbelzinnig de jou waarlijk gegeven functie. Over de gegrondheid daarvan bestaat geen twijfel. Ze komt van Iemand die geen vergissingen kent, en Zijn Stem is zeker van Haar boodschappen. Die zullen niet veranderen, noch tegenstrijdig zijn. Ze wijzen alle naar één doel, een dat jij kunt bereiken. Jouw plan is misschien onmogelijk, maar dat van God kan nooit mislukken, omdat het in Hem zijn Oorsprong vindt.Doe zoals Gods Stem aangeeft. En als die iets van jou vraagt wat onmogelijk lijkt, denk er dan aan Wie het is die vraagt, en wie het is die weigert. Overweeg dan dit: wie heeft het ‘t meest waarschijnlijk bij het rechte eind? De Stem die namens de Schepper van alle dingen spreekt, die alle dingen precies kent zoals ze zijn, of een vervormd beeld van jezelf, verward, onthutst, onsamenhangend en onzeker van alles? Laat je niet leiden door die stem. Hoor in plaats daarvan een zekere Stem die jou vertelt van een functie die jou gegeven is door jouw Schepper, die Zich jou herinnert en jou aanspoort dat jij je Hem nu herinnert.Zijn zachte Stem roept vanuit het gekende naar de onwetenden. Hij wil jou troosten, ook al kent Hij geen droefheid. Hij wil een teruggave verlenen ook al is Hij compleet: een gave aan jou, ook al weet Hij dat jij alles al hebt. Hij heeft Gedachten die een antwoord zijn op elke behoefte die Zijn Zoon bespeurt, ook al ziet Hij ze niet. Want Liefde moet geven, en wat in Zijn Naam wordt gegeven neemt die vorm aan welke in een wereld van vormen het meest bruikbaar is.Dit zijn de vormen die nooit kunnen misleiden, omdat ze uit Vormloos heid zelf voortkomen. Vergeving is een aardse vorm van liefde die, zoals ze in de Hemel bestaat, geen vorm bezit. Maar wat hier nodig is wordt hier gegeven zoals het nodig is. In deze vorm kun je zelfs hier je functie vervullen, hoewel wat liefde voor je zal betekenen wanneer vormloosheid jou teruggegeven is, nog grootser is. De verlossing van de wereld hangt af van jou die kan vergeven. Dat is jouw functie hier.Alle tekst- werk en handboek klassen van Een Cursus in Wonderen met Elbert nu te beluisteren en te bekijken op https://decursusmetelbert.nl

"What I appreciate about our patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia is the consideration that they receive a cancer diagnosis, and the best thing for them to do is actually nothing. There is a large population of patients that we don't recommend any type of treatment. We recommend that they establish care with an oncologist and that they have a relationship with those care teams," ONS member Caitilin Murphy, DNP, APRN, FNP-BC, AOCNP®, chief nurse practitioner at Dana-Farber Cancer Institute in Boston, MA, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about an overview of CLL for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 3, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge of the diagnosis and management of chronic lymphocytic leukemia. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 339: A Lesson on Labs: How to Monitor and Educate Patients With Cancer Episode 256: Cancer Symptom Management Basics: Hematologic Complications ONS Voice articles: Compensation Funds Curb Financial Burden for Certain Exposure-Related Cancers Infection Prevention for Oncology Nurses Nurse-Led Bone Marrow Biopsy Clinics Truncate Time for Testing, Treatment Patient Stress Linked to More Advanced Leukemia Patients With CLL Report Worse QoL and Other Factors Clinical Journal of Oncology Nursing articles:  Care Coordination: Overcoming Barriers to Improve Outcomes for Patients With Hematologic Malignancies in Rural Settings Pseudohyperkalemia in Chronic Lymphocytic Leukemia: An Often Overlooked Clinical Entity Richter Transformation Arising From Chronic Lymphocytic Leukemia ONS book: Site-Specific Cancer Series: Leukemia (first edition) Hematology, Cellular Therapy and Stem Cell Transplantation Learning Library ONS Biomarker Database ONS clinical practice resource: Genomics Taxonomy Blood Cancer United: Chronic Lymphocytic Leukemia: In Detail CLL Society: Patient Education Toolkit Lymphoma Research Foundation: Lymphoma and CLL Publications National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Some of the common risk factors are environmental exposures, occupational exposures, and chemical exposures. For example, in certain farming communities where there are pesticides, that can definitely contribute to the risk of developing CLL. There's some consideration for high levels of radon exposure or exposure to Agent Orange. So our veterans, both from the Vietnam War but also more recently in Iraq. There's definitely a consideration that those types of exposures increase the risk of developing CLL." TS 3:01 "Generally, the average age of diagnosis for CLL is in the seventh decade of life. But over 90% of people are diagnosed at age 50 and above. So, this tends to be a diagnosis in the six or seventh decade of life. It's extremely rare in children, although it has been observed, and it's twice as likely to develop in men than it is compared to women. And then individuals who are White are more frequently affected by CLL than other racial or ethnic groups, followed by people of color. And that includes Black, Hispanic, and Native American individuals, but it's rarer in Asian populations." TS 9:33  "There's a lot of adjustment and coping with a new diagnosis. When we think about the diagnostic approach, we get a lot of information that's incredibly valuable and helps us really to pivot and guide patients as to where they need to go and how we can best support them. We've had well-established studies that look to say, 'If we were to treat patients earlier or have different thresholds for consideration for treatment, do patients do better?' ... I think it's really great that we can actually guide patients in a much more precise way, that you don't need any type of therapy at this point, and it may change and evolve in the future." TS 20:29 "I have some patients that are doers and they want to do something, so this active surveillance or watch and wait really paralyzes their coping. And so they want to do something. Oftentimes, that's really when I pull in some integrative strategies and say exercise is always going to be beneficial. The more active you are, the more physically fit you are. If you really want to do something, make sure that you stay hydrated, that you eat well, and you're engaged in a physical activity that you enjoy and can be consistent with." TS 32:37 "I think another piece that we don't often discuss is around the immunoglobulins and the immune system, but CLL has a pretty significant impact on immune dysfunction. And so patients with CLL, even if they are not on any type of active treatment, their immune system doesn't necessarily function fully. And so they're more likely to develop some upper respiratory infections or more easily develop the flu or coronavirus. ... Often times, we think a lot about supporting patients to get vaccines and to have early evaluation if those symptoms develop because you're more likely to develop upper respiratory infections. I think there's a component around immune dysfunction that I think is really valuable for people to understand that it's not contingent upon the treatment. It's contingent upon the disease and mechanistically, how the B cells are dysfunctional and don't provide that immunity that otherwise would be in a healthy B cell." TS 42:54

Netbeheerders die toegang tot het stroomnet weigeren, concurrentie van grote commerciële energieleveranciers én een energiecrisis als gevolg van de oorlog in het Midden Oosten. Hoe gaat cooperatieve energieleverancier Energie van Ons om met al deze uitdagingen? André Dippell, algemeen directeur van coöperatieve energieleverancier Energie van Ons is te gast in BNR Zakendoen. Macro met Mujagić/Boot Elke dag een intrigerende gedachtewisseling over de stand van de macro-economie. Op maandag en vrijdag gaat presentator Thomas van Zijl in gesprek met econoom Arnoud Boot, de rest van de week praat Van Zijl met econoom Edin Mujagić. Ook altijd terug te vinden als je een aflevering gemist hebt. Blik op de wereld Wat speelt zich vandaag af op het wereldtoneel? Het laatste nieuws uit bijvoorbeeld Oekraïne, het Midden-Oosten, de Verenigde Staten of Brussel hoor je iedere werkdag om 12.10 van onze vaste experts en eigen redacteuren en verslaggevers. Ook los te vinden als podcast. Boardroompanel Het Nederlands Fotomuseum moet diep in de buidel tasten na een onterecht ontslag. En: ASR biedt excuses aan voor de rol van zijn rechtsvoorgangers in de slavernij. Dat en meer bespreekt presentator Thomas van Zijl vanaf 11.00 in het Boardroompanel met Ilona Haaijer, president-commissaris bij Corbion en non-executive director bij Glanbia, en Lieve Declercq, directeur van spoor- en bouwbedrijf Strukton. Luister l Boardroompanel Zakenlunch Elke dag, tijdens de lunch, geniet je mee van het laatste zakelijke nieuws, actuele informatie over de financiële markten en ander economische actualiteiten. Op een ontspannen manier word je als luisteraar bijgepraat over alles wat er speelt in de wereld van het bedrijfsleven en de beurs. En altijd terug te vinden als podcast, mocht je de lunch gemist hebben. Contact & Abonneren BNR Zakendoen zendt elke werkdag live uit van 11:00 tot 13:30 uur. Je kunt de redactie bereiken via e-mail. Abonneren op de podcast van BNR Zakendoen kan via bnr.nl/zakendoen, of via Apple Podcast en Spotify. See omnystudio.com/listener for privacy information.

"There are a huge array of medical dynamics that people endure, and when they leave a lasting impact, a word that we don't use widely enough is the word 'trauma.' There's an entire category of phenomena in the medical arena that are, in fact, traumatic. One way we know that these experiences are traumatic is that we know that huge portions of people who experience things like cancer do indeed develop problems like [post-traumatic stress disorder]," James C. Jackson, PsyD, research professor at Vanderbilt University Medical Center in Nashville, TN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about understanding medical trauma in oncology. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 26, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge of medical trauma and its effects on patients with cancer, caregivers, and healthcare professionals. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 315: Processing Grief as an Oncology Nurse Episode 287: Tools, Techniques, and Real-World Examples for Difficult Conversations in Cancer Care Episode 276: Support Young Families During a Parent's Cancer Journey Episode 257: Redefining the Bell: The Ethics of Hope for Oncology Nurses and Patients Episode 103: What Oncology Nurses Need to Know to Support Caregivers ONS Voice articles: 'Between Two Kingdoms' Gives Us a Glimpse Into How Patients and Families Experience Malignancy AYA Cancer Survivors Experience Five Times Higher Depression Rates Than Individuals Diagnosed at Older Ages From Stigma to Support: Changing the Cancer Conversation Help Caregivers Control the Chronic Stress of Cancer Care and Manage PTSD Moral Injury and Trauma in Nursing Trauma-Informed Care Provides Person-Centered Support for Patients During Deep Distress When the Story Ends, Cancer Does Not Win: Reframing Death in Terminal Cancer Care Word Choice Matters When Caring for Patients With Cancer ONS course: ONS Psychosocial Dimensions of Cancer Care™  Clinical Journal of Oncology Nursing articles: Psychosocial Barriers to Care: Recognizing and Responding Through a Trauma-Informed Care Approach Trauma-Informed Care Addressing the Mental and Emotional Needs of Patients With Cancer Oncology Nursing Forum articles: Post-Traumatic Distress and Symptom Experience in Patients With Head and Neck Cancer–Related Tracheostomy and Family Caregivers The Effect of Neuroticism, Fear of Progression, and Self-Efficacy on Post-Traumatic Growth in Patients With Lung Cancer Undergoing Chemotherapy Reclaiming Your Life From Medical Trauma by James C. Jackson To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Many people have a notion about what medical trauma is, but perhaps they lack a definition. I use a definition that is deliberately broad because I think it is better to be inclusive than exclusive. A medical trauma to me is a medical experience or a medical encounter that basically leaves a mark. It leaves an emotional mark, and that mark is significant enough to disrupt your daily life." TS 2:06 "When somebody develops a life-threatening illness—let's say cancer—it's not their problem only. It's very much a family problem. It affects any manner of people. There is literature that says that family members of people with life-threatening conditions often have rates of PTSD that are every bit as high as the patients do. There's also literature that says that if we can identify this issue as a family problem—a family challenge, not just an individual challenge—then very often that patient is going to do better." TS 8:23 "We just need to make space for people to feel however they feel. And we need to emphasize, I think, that in some ways, even though there's no cancer on the scan, cancer casts a long shadow in the lives of people, which is why when patients after cancer see their primary care provider, when they come back for a checkup with oncology, we need to continue this conversation of 'How is your mental health? Are you okay? How's your anxiety? How are you managing?' … We need to be really curious and kind, and we need to query people about how they're doing, even if officially they don't have cancer." TS 16:20 "Trauma-informed care has become a bit of a buzzword in our culture. But when it is engaged correctly, I think it's really important. And I think in a nutshell, what it means is that as providers, we need to recognize that some situations and circumstances are likely to be traumatic, and we need to pivot and engage people differently now that we know that. Specific features of trauma-informed care might be we're really going to value your emotional safety. We're going to emphasize that. We are going to emphasize boundaries. We are going to ask your permission instead of telling you how to do things. We are going to be really attentive to the language we use to engage you because we're aware of there might be things about your situation that are really triggering." TS 28:15 "I think one [misconception] certainly is that it is only afflicting and affecting people who are frail or weak—not very strong. That's emphatically not true. But that's a popular misconception—that if I'm strong enough, if I'm resilient enough, this experience will not be traumatic to me. It's just not true. Medical trauma doesn't just happen in emotionally weak people. Medical trauma can impact people of all sorts." TS 33:42 "The other misconception, I think, is that there is no hope for people in the throes of medical trauma. I'm not advocating 'hopium,' It's a term that was coined, I think, during the pandemic. I don't think that living with medical trauma is all rainbows and unicorns and shiny things. But the truth is, if you get the treatment that you need, you can find a way to thrive with medical trauma even as you're impacted by medical trauma. This, this 'both-and-ness' is really true. You can both be adversely affected and you can even find some beauty in your struggle. Both can be true." TS 34:13 "I wish people understood that there is a name for this phenomenon. We're naming it here today medical trauma. Not everyone who has cancer has medical trauma—not even close—but there are many people who do. And I think many of those people, they don't quite have a name for it. And when I introduce this name for it—trauma—many of them say, 'Oh, my gosh, that makes so much sense. I didn't quite understand why I was struggling so much with this. I didn't quite understand why it casts such a long shadow in my life. I didn't really understand why I was having panic attacks every time I had to get another scan at the oncology office to see if my breast cancer had returned. Now I understand. Now I understand it's because it was trauma.'" TS 35:09

Sex! Damit kriegen wir doch hoffentlich eure Aufmerksamkeit? Haben sich auch Romano und Claudia Kamieth gedacht - ihr habt im Blue Moon über euer Sexleben ausgepackt! Egal ob Online-Dating, ONS oder sexlos - ihr habt davon erzählt. Unser Podcast-Tipp: Wissen mit Johnny https://www.ardsounds.de/sendung/wissen-mit-johnny/urn:ard:show:5c94752475c8acfc/

El séptimo álbum que lanzan The Hanging Stars en su década de trayectoria marca la cumbre creativa de la banda liderada por Richard Olson. Con “Just a day” los británicos nos embarcan en un viaje emocional arropado por guitarras tintineantes, armonías vocales, melodías ensoñadoras y una refinada receta de country, pop, folk y psicodelia. Un álbum en donde mandan las canciones. Posiblemente el disco más bonito que hemos escuchado este año.(Foto del podcast por Dean Chalkley)Playlist;THE HANGING STARS “All your yesterdays”THE HANGING STARS “Just a day”THE HANGING STARS “Show me the way”THE HANGING STARS “Think I’ll be alright”COURTNEY BARNETT “Site unseen”SLIPPERS “Sunday morning”KURT BAKER “Hanging on the telephone”PAUL COLLINS “Hang on to yourself”THE ON and ONS “Kooks”SPEEDWAYS “LunaRADIO DAYS “One heart, one love”THE ROLLING STARS “Stars”LENNY KAYE “The things you left behind”GREY and GREENE “That’s all”DEWOLFF “Let’s stay together”COLE BERLINER “A Western sun”ALLAH-LAS “Ultramarine”Escuchar audio

Van onze Correspondent is een serie van de makers van podcast De Dag. Iedere zondag maken we kennis met een van de correspondenten van de NOS, het land waar ze wonen, en de verhalen die wat hen betreft meer aandacht verdienen. Vandaag: Daisy Mohr, correspondent in het Midden-Oosten. Sinds 2002 woont Daisy al in de Libanese hoofdstad Beiroet. Ze ging erheen om Arabisch te studeren, vond in haar eerste week daar al de liefde waar ze later mee trouwde en begon snel met werken voor de krant Het Parool. “Ik was gefascineerd door die contrasten, al die verschillende landen wilde ik graag ontdekken en de politiek natuurlijk”. Mohr werkte jarenlang voor kranten en achter de schermen produceerde ze verhalen voor haar voorgangers op deze post. In die ruim 20 jaar daar gebeurden er hele grote dingen: van de invasie van Irak tot de zoveelste oorlog nu met Israël. En al die jaren loopt Mohr rond in die gebieden waar het ook onrustig en onveilig is. “Ik probeer altijd te blijven op plekken waar het risico behapbaar is. Maar het is veel lastiger als je woont op de plek waar het oorlog is. Ons gezin woont nu in de oorlog.” Sinds 2019 is ze de correspondent voor de NOS in het Midden-Oosten. Ze gaat altijd op pad met haar vaste cameravrouw Edmee van Rijn, die ook even inbelt in de podcast. Met een tasje vol snacks trekken ze als team van twee vrouwen samen naar de verhalen en dat heeft zo z'n voordelen: “voor ons gaan deuren open, die voor mannen gesloten blijven”. Het regelen van visa's vinden veel correspondenten heel vervelend, maar Mohr geniet ervan: “ik heb van m'n hobby m'n werk gemaakt”. Cultuurtip: Fairuz - El Bosta En met Daisy Mohr is deze serie Van onze correspondent tot een eind. In het najaar maken we weer nieuwe afleveringen met de andere correspondenten. Wil je reageren? Mail naar dedag@nos.nl (mailto:dedag@nos.nl). Presentatie & montage: Marco Geijtenbeek Redactie: Max Smedes & Rosanne Sies

"We typically think of the disease progressing for our higher-risk patients because many of them already start with increased blasts or a lot of dysplasia. And they have these chromosomal variants that make them prone to evolving into acute myeloid leukemia (AML). With them, we can anticipate that they are going to progress to AML. And that's what we're trying to prevent. It's kind of like a biologic evolution and not a switch," ONS member Sara Tinsley-Vance, PhD, APRN, AOCN®, nurse practitioner and quality-of-life researcher at Moffitt Cancer Center in Tampa, FL, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about long-term myelodysplastic syndrome (MDS) considerations for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 19, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to management of long-term side effects related to myelodysplastic syndrome and its treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 415: Myelodysplastic Syndrome Treatment Considerations for Oncology Nurses Episode 411: An Overview of Myelodysplastic Syndrome for Oncology Nurses Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 220: Oncologic Emergencies 101: Febrile Neutropenia and Sepsis Clinical Journal of Oncology Nursing articles:  Exploring Experiences of Bereaved Caregivers of Older Adult Patients With Acute Myeloid Leukemia Family Caregiver Preparedness: Developing an Educational Intervention for Symptom Management Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery Oncology Nursing Forum article: An Integrative Review of Sex Differences in Quality of Life and Symptoms Among Survivors of Hematologic Malignancies ONS book: BMTCN® Certification Review Manual (second edition) ONS course: Psychosocial Dimensions of Cancer Care™  ONS Learning Libraries:  Survivorship Learning Library Hematology, Cellular Therapy, and Stem Cell Transplantation Survivorship Care Plan Huddle Card American Association of Colleges of Nursing End-of-Life Nursing Education Consortium (ELNEC) American Cancer Society: Living As a Myelodysplastic Syndrome Survivor American Society of Hematology Aplastic Anemia and MDS International Foundation: MDS Toolkit Blood Cancer United: Myelodysplastic Syndromes Family Caregiver Alliance HealthTree Foundation Inspire: MDS Support and Discussion Community Myelodysplastic Syndromes Foundation To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "When our higher-risk patients have disease-related progression, their [malignancy] can transform to AML. And we know this occurs in about one-third of our patients and is one of the most serious late effects. Even in lower-risk disease, we have this worsening marrow failure with or without increasing blast, where [patients] may have just started out with anemia, then they also develop neutropenia and thrombocytopenia. And as those counts worsen, we usually know that their disease is progressing." TS 2:47 "The golden rule is looking at the blood count but also looking at the patient and how they're doing over time. The backbone of MDS monitoring is the complete blood cell count with the differential. What you're looking for is trends over time. How many units of blood are they receiving, what threshold are you going to transfuse them at, and how many units of blood are they getting at a time? ... And then paying attention to the absolute neutrophil count for infection risk. [Another] really important piece of when you look at the differential with patients is seeing if they have any abnormal cell counts. Do they have circulating blasts? Are those monocytes going up? If you start to see blasts circulating or increasing monocytes, then their disease could be changing, even if they have low-risk disease." TS 15:58 "For lower-risk disease, we're paying more attention to their quality of life, how the patient's tolerating therapy, trying to help them stay safe over the long haul, and starting them on iron chelation if it matches that patient and they can have access to those drugs. ... For higher-risk disease, if the patient's goal is to be cured and not to progress to AML, you want to get them to transplant if that's [also] one of their goals. If they do evolve into AML, try and see what treatment matches best for them." TS 22:28 "You want to start early for patients who have febrile neutropenia—that's really important when a patient is an hour or two away from a center where they can get started on antibiotics. So, you have to think outside the box. What can we do to keep them safe? ... I know this group in Alaska that's in our advisory meetings and they try to facilitate transportation to Seattle. That's the closest academic center to them. Collaborating with telemedicine appointments, starting earlier, developing that strong relationship with patients, and contacting them between visits [can help patients living in rural areas]." TS 25:22 "I think the biggest [psychosocial challenge] I see is a lot of unmet anxiety and depression counseling. A lot of times, [patients are] losing their place in their family because they're the ones that need all the help now. Also, the uncertainty that goes along with the diagnosis. There is communication skills counseling, and End-of-Life Nursing Education Consortium (ELNEC) has a lot of training for communication skills and how to really talk to patients. Not that we take the place of a psychologist, but just being able to talk to somebody can go a long way. And if we can get training for that, we can help more patients." TS 31:15

"Until immunomodulators, patients [with myeloma] did not have a great overall survival rate. But when we introduced lenalidomide, we started seeing our patients have life expectancies between five and seven years—which was unheard of prior to these immunomodulators going forward. I think it's promising and allows patients to have quality of life versus therapy of life," ONS member Daniel Verina, DNP, RN, ACNP-BC, nurse practitioner for the multiple myeloma program at Mount Sinai Medical Center in New York, NY, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about immunomodulators. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 12, 2027. Daniel Verina is on the speakers' bureau for Johnson & Johnson, GlaxoSmithKline, and Pfizer. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome:  Learners will report an increase in knowledge about the use of immunomodulators to treat cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 401: Multiple Myeloma Treatment Considerations for Oncology Nurses Episode 386: Interprofessional Navigation and the Oral Anticancer Medication Care Compass Episode 290: Cancer Symptom Management Basics: Peripheral Neuropathy ONS Voice articles: Maintain Oral Adherence With ONS Guidelines™ Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations Sexual Considerations for Patients With Cancer Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum articles: Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS book: Multiple Myeloma: A Textbook for Nurses (third edition) ONS Symptom Intervention resource: Peripheral Neuropathy Risk Evaluation and Mitigation Strategies (REMS) Lenalidomide Pomalidomide Thalidomide International Myeloma Foundation: Using Immune Therapy to Fight Multiple Myeloma International Myeloma Society Multiple Myeloma Research Foundation: Treatments for Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We definitely want the diagnosis of multiple myeloma before initiating these drugs. We're going to look at serum protein electrophoresis. We want to make sure that we know the patient has serum free light chains and myeloma proteins to really confirm their disease. Plus, a bone marrow biopsy." TS 7:21 "Each immunomodulator has slightly different side effects. Thalidomide's biggest side effects are constipation, weakness, fatigue, somnolence, peripheral neuropathy, mood swings, hand tremors, and depression. With each generation, less of the side effects actually occurred. Most of lenalidomide's side effects, not discounting the deep vein thrombosis, are pancytopenia—the neutropenia, the anemia, and the thrombocytopenia. [The side effects] are very similar in pomalidomide." TS 15:40 "The REMS program is critical for oral immunomodulator therapies—thalidomide, pomalidomide, and lenalidomide. It was developed due to the risk of developing embryofetal toxicities. ... It is mandatory testing and counseling, so all females of reproductive potential must have two negative pregnancy tests prior to starting the therapy and then monthly pregnancy tests while on the therapy alone. Again, they must use two forms of effective contraceptives or abstain from heterosexual sex four weeks prior, during, and after. And the same thing for men. I focus on that because males may say, 'I have a vasectomy.' These therapies tend to bind to the semen. So, males must still use a latex or synthetic condom during any sexual contact with a female of reproductive potential, even if they did have a vasectomy." TS 18:31 "The capsule itself cannot be chewed, crushed, or opened. I bring that up because as healthcare professionals, we have educated our patients. If it's difficult to swallow capsules or tablets, we've always said to them, 'Oh, don't worry, just crush it into applesauce or open it up and sprinkle it on your mashed potatoes.' But because of this embryofetal toxicity, I advise my patients not to open the capsule. If they can't swallow it for any reason, they have a sore throat or they're just unable to, then [we tell them] to hold the therapy and then call us." TS 22:49 "We spoke about three generations already, but there's actually a fourth generation [of immunomodulators]. They're called cereblon E3 ligase modulators(CELMoDs). They're still in clinical trials but really showing promise in the therapy of myeloma. They're showing very good affinity to cereblons, just like the immunomodulators do. I think, in all cancer therapies, as newer generations come out or newer therapies move forward, some of the older generations might move aside, but they get integrated later on. So I don't think [immunomodulators] will disappear totally, but they will probably be modified." TS 36:39

Vergeet de maanlanding en de uitvinding van elektriciteit. Volgens Infantino is dit de grootste gebeurtenis in de geschiedenis van de mensheid. Naast het WK voetbal bedoelde Gianni ook zeer waarschijnlijk het WK-fé van De Derde Helft. Iedere vrijdag stijgt de Oranjekoorts in deze studio namelijk naar ongezonde hoogte. Ook wij gaan starten. Welkom bij het eerste WK-fé van 2026, met als eerste gast Humberto Tan.

Births in England and Wales have fallen again, for the fourth record-low year in a row, and the numbers are not exactly whispering. They are standing in the kitchen at midnight, holding a mug of tea, saying, “We may have a problem here.”In this episode of Mark and Pete, we look at the dramatic fall in the birth rate, the latest ONS figures, and what they reveal about family, fertility, money, housing, culture, marriage, and the strange modern habit of treating children as both priceless blessings and impossible luxury goods.England and Wales recorded 585,396 live births in 2025, down from 594,677 in 2024. The total fertility rate fell to around 1.39 children per woman, far below the usual replacement level of about 2.1. Back in 1970, there were 784,486 live births and the fertility rate was around 2.40. In plain English, we are having far fewer babies than we used to, and not by a polite little margin either.We also discuss the wider fertility picture, including studies suggesting sperm counts may have fallen sharply since the 1970s. That does not prove the birth-rate collapse is biological, and no, we are not about to blame the entire thing on plastic bottles and sad sandwiches. But it does suggest the story may be deeper than lifestyle choice alone.So why are people having fewer children? Is it housing? Childcare costs? Delayed marriage? Economic anxiety? Cultural exhaustion? A loss of hope? Or simply the fact that modern life appears to have been designed by a committee of accountants who once saw a family from a distance?From a Christian perspective, children are not merely demographic units. They are gifts, blessings, futures, interruptions, joys, terrors, and little walking reminders that life is meant to continue.A sharp, thoughtful and sardonic look at Britain's falling birth rate, fertility decline, family life, and what happens when a nation quietly stops expecting tomorrow.

Het Nederlands elftal trainde vrijdag voor het eerst op Amerikaanse bodem. Ons team was erbij en in de AD Voetbalpodcast praten Etienne Verhoeff en Maarten Wijffels je vanuit New York bij over Oranje en de WK-sfeer in de Verenigde Staten. Ook het overlijden van voormalig teammanager Hans Jorritsma komt aan bod. Verder praten ze over outsider Noorwegen, de man van 150 miljoen en de fout van Marc van Hintum bij Go Ahead Eagles. De technisch directeur stuurde de vertrekkende trainer Melvin Boel per abuis de lijst met mogelijke opvolgers via WhatsApp. Beluister de AD Voetbalpodcast via AD.nl, de AD App of jouw favoriete podcastplatform. Bestel het boek De vraag van Vandaag hier: https://webwinkel.ad.nl/product/de-vraag-van-vandaagSupport the show: https://krant.nl/See omnystudio.com/listener for privacy information.

"Radiation therapy is often extremely well tolerated in colorectal cancer. Technology has really changed things. But location of the tumor can affect side effects, such as radiation dermatitis. If a patient has a low-lying tumor, if it's less than six centimeters from the anal verge, the patient is likely to have some skin reaction. It's good to be proactive if that's the case," ONS member Lorraine Drapek, DNP, FNP-BC, AOCNP®, nurse practitioner in the Department of Radiation Oncology at Massachusetts General Hospital in Boston, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation side effects in colorectal cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 5, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the side effects of radiation to treat colorectal cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 374: Colorectal Cancer Treatment Considerations for Nurses Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer High-Fiber Diet Reduces Diarrhea in Colorectal Cancer Survivors Hyperbaric Oxygen Therapy Shows Promise for Certain Radiation Side Effects Increasing Incidence of Colorectal Cancer in Younger Adults Is a Call to Action for Oncology Nurses Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin Oncology Nurses Are Key in Sexual Health Conversations With Minority Women Sexual Considerations for Patients With Cancer The Intersection of Pelvic Health and Oncology Optimizes Sexual Symptom Management ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS/ONCC® Radiation Therapy Certificate™ ONS ROCN™ Certification Review™ Clinical Journal of Oncology Nursing articles: Sexual Dysfunction: Common Side Effect Updated Interventions for Radiation-Induced Diarrhea: Putting Evidence Into Practice With the Oncology Nursing Society Physical Activity: A Systematic Review to Inform Nurse Recommendations During Treatment for Colorectal Cancer ONS Learning Libraries: Colorectal Cancer Radiation Advanced Practitioner Society for Hematology and Oncology American Society for Radiation Oncology American Society of Clinical Oncology Clinical Practice Guidelines Colontown Colorectal Cancer Alliance To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "In recent years, there has been more nonsurgical management of rectal cancer, especially in what we call the low-lying population. This is the population of patients who would likely end up with a permanent colostomy because their cancer is so low in terms of being close to or involving the anal verge. There is now a regimen where these patients can get their chemotherapy followed by their chemoradiation and then be monitored on close surveillance without surgery." TS 2:23 "Another assessment would be to assess what effects have they had from their chemotherapy that they're bringing with them. FOLFOX-based treatment is commonly used, and the platinum therapy oxaliplatin often causes peripheral neuropathy. What is the patient having? What are those symptoms like? Are they having peripheral neuropathy? If they are that is likely not going to get better or improve during their whole course of radiation. In fact, sometimes when oxaliplatin therapy stops, the peripheral neuropathy can get worse as patients are going through other treatments." TS 5:42 "If the patient has a low-lying tumor, if it's less than six centimeters from the anal verge, the patient is likely to have some skin reaction. It's good to be proactive if that's the case. And then proactively minimizing radiation dermatitis effects, such as keeping the area clean, good washing of the area, and prophylactically starting them on or having someone start them on steroid creams a couple of times a day to minimize that radiation dermatitis effect in the long run." TS 7:25 "I have a sexual health clinic for women with these effects. It's very important as nurses that if you can develop the comfort to ask patients about their sexual activity—it's hard, but it really needs to be done. And I will tell you that the healthcare providers are not doing it. They don't have time, and like us as nurses, we don't get this in school, and neither do they. The other providers don't get it in school either, but it's important. Patients are getting more and more worried about their sexual health. They're coming to us at a younger age, and this is really, really important to address." TS 15:35 "I would say that working with your advanced practice providers and education for advanced practice providers has definitely been focusing on [sexual health] more. Your PAs and your NPs—I think they're going to have the ears and the wherewithal to be able to be your allies and colleagues in this. By and large, it's my APP colleagues and nursing that I talk to the most about this. … Again, it's not an easy thing to bring forward, having dilators in place. But I will tell you in the department that I work in, it was me and couple of nurses who pushed this issue with the physicians for two years and finally got it put in place. It can be done. There's a lot more centers out there doing that." TS 21:51

"There are a lot of specifics that nurses need to keep in mind as they are administering this herpes simplex modified virus to patients because accidental exposure is of concern both to the patient, to their family members, as well as to healthcare workers. I always recommend nurses wear personal protective equipment, such as a gown, safety glasses, gloves, and/or a face shield," Heidi Finnes, PharmD, RPh, BCOP, director of clinical ambulatory practice at Mayo Clinic and assistant professor of pharmacy at Mayo Clinic Alix School of Medicine in Rochester, MN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about oncolytic viral therapy.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 29, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge about the use of oncolytic viruses to treat cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 273: Updates in Chemotherapy and Immunotherapy ONS Voice articles: Cutaneous Malignancies Have High Response to Oncolytic Virus Plus Immunotherapy Oncolytic Virus Kills Tumor Cells While Supporting T Cells What Nurses Need to Know About Talimogene Laherparepvec for Advanced Melanoma Clinical Journal of Oncology Nursing articles: Intralesional Therapy: Consensus Statements for Best Practices in Administration From the Melanoma Nursing Initiative Safe and Effective Standards of Care: Supporting the Administration of T-VEC for Patients With Advanced Melanoma in the Outpatient Oncology Setting Oncology Nursing Forum article: Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma ONS book: Guide to Cancer Immunotherapy (second edition) ONS clinical practice resource: Safe Handling of Oncolytic Viruses ONS Huddle Card: Immunotherapy Association of Community Cancer Centers (ACCC) Drugs@FDA Hematology/Oncology Pharmacy Association (HOPA) Network for Collaborative Oncology Development and Advancement (NCODA) Patient Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "[Oncolytic viruses] can have direct lysis to the tumor cells themselves, or they can cause immunogenic activation. They release tumor-associated antigens and then proinflammatory signals, so think of T cells, natural killer cells, those sorts of things, that can convert to immunologically cold tumors. Those are tumors that are immune silenced into hot tumors which are now immune activated. By doing that, they recruit those T cells and other cells to the area to attack both the primary tumors. But that's also thought to be how they work on distant or noninjected sites as well. This immunomodulatory capacity has led to the reclassification of oncolytic viruses as a form of cancer immunotherapy. So, think of it kind of similarly to how we think of immune checkpoint inhibitors in recruiting immune cells and leaving our immune system in the on position. This is also kind of a form of immunotherapy." TS 4:35 "One of the toxicities I know that is of significant concern to patients, family members, and healthcare workers is the incidence of herpes infections. Systemic herpetic infections are extremely rare and usually more common in patients who may be immunocompromised. In patients who also have other immune-related diseases—such as vitiligo, vasculitis, pneumonitis, sometimes worsening psoriasis—because you're mounting an immune response with these types of things, sometimes you can see a worsening of those types of immune symptoms. But for the most part, these types of side effects are very well tolerated in most patients." TS 9:07 "Talimogene is generally transmitted via bodily fluids or touch. It's not airborne. Herpes simplex virus isn't an airborne type of virus. Another thing to consider is where are you going to inject this? Are you going to do this in your infusion therapy unit? Are you going to do it in a dedicated room? Who's going to escort the patient to the room? How is the virus going to arrive at the room? How will you clean the room and all of the laboratory equipment or any of the exam tables that may be in there? I think having all of that discussed and assigned mitigates the consternation that can sometimes occur—the fear that occurs with administering a virus that is thought to be fairly communicable." TS 15:44 "Helping patients understand how this works [is important] because hearing that you're receiving a virus, particularly a herpes simplex virus, can be scary to a patient. I think understanding that it's modified or essentially we're taking the parts out of it so that we can directly inject a portion that recruits immune cells to that area, because the goal is for the oncolytic virus to attack cancer cells and then destroy them by triggering an immune response in the body." TS 20:51 "Sometimes patients are very concerned about urine in the toilet, bodily fluids, kissing loved ones, holding hands, hugging, you know, am I going to infect my loved one because I'm getting this type of an oncolytic virus therapy? I like to reassure patients that they can continue to hold hands and hug their loved ones as normal. Viral DNA is usually only present on the injection site. And as I mentioned previously, we want to cover that injection site with an occlusive dressing, at least with talimogene, for up to seven days. And particularly, if those injection sites are at all oozing or weeping, active virus is usually only on that injection site itself." TS 24:14

"When you have benign conditions, we're actually treating 3 gray, so a significant difference [versus doses of 60 gray for brain cancer]. Typically, when you treat at a high dose, the goal is to destroy tissue, like cancer tissue or cancer cells. But when we give a low dose, the goal is actually to modulate inflammation. And what it does is it slows down those inflammatory cells or those cells that release the chemicals that cause pain and inflammation," Amanda Meyer, DNP, APRN, CNP, family nurse practitioner in the Department of Radiation Oncology at the Mayo Clinic in Rochester, MN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation therapy for noncancer indications. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 22, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge about the use of radiation to treat noncancerous conditions. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 365: Radiation-Associated Secondary Cancers Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices ONS Voice articles: Augmented Reality Simulations Reduce Patient Anxiety by Teaching Them About Radiation Therapy Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education Quick Quiz: Test Your Knowledge of Radiation Care Coordination ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS Radiation Oncology Conference Recordings Bundle™ ONS ROCN™ Certification Review™ Radiation Oncology 101: 2024 ONS Bridge™ Session ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Findings From the 2023 Radiation Oncology Nursing Role Delineation Study to Shape the Future of the Subspecialty The Role of Advanced Practice Providers in Radiation Oncology in 2025 ONS Huddle Cards: Radiation Radiobiology German Society for Radiation Oncology (DEGRO): Guidelines in Radiotherapy: Radiotherapy for Benign Diseases To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We always typically think of it as cancer treatment, but we can use radiation for noncancerous conditions, as well. And radiation was actually used for benign diseases right after the discovery of x-rays. By the 1920s it was used a lot for different types of musculoskeletal, dermatologic issues, and different types of inflammatory conditions. And over time, since the 1920s, we've actually really gotten a really good understanding of it." TS 1:37 "When we're looking at what are good candidate characteristics, we do typically like older patients, so patients over the age of 65. And the rationale behind that is we know that there is a potential for a secondary risk of a skin cancer about 20 to 30 years after getting low-dose radiation, like a basal cell or squamous cell skin cancer. The older the patient is, the less likely they are to have any adverse effects from that." TS 8:22 "When we do the low-dose radiation, they've tried other measures that haven't been successful. However, we don't want a patient who is so severe that they're ready for surgery, when they're bone on bone, because we know that radiation isn't as effective when they are that severe. So there's this sweet window where low-dose radiation works best in these patients." TS 9:39 "When we're treating with a little bit higher dose for like a Dupuytren's or a Ledderhose, because it's an anti-proliferative dose, those patients, they do get more skin redness, more dry skin. That's very temporary, and it resolves within a week or two after treatment. But really, we don't see any acute side effects. The long-term side effect of the radiation-induced malignancy, again, is a very low—0.05% according to some of the European guidelines." TS 12:34 "I really wish people appreciated how interdisciplinary this is. We need to get referrals from family medicine and from primary care and internal medicine and pain medicine physicians and inflammatory physicians and podiatry and pain specialists. And we really need to use this multidisciplinary approach to get earlier referrals for patients because there is this sweet window of time where low-dose radiation works the best." TS 18:40

"We want to make sure that we discuss the details of the treatment and what treatments there are, whether it's an oral drug, whether it's a subcutaneous injection or an IV injection, [the patient's] potential for responding, whether this treatment is curative or supportive, and what the number of visits are. All of those different pieces of information that go into the decision-making process are really important," ONS member Sara Tinsley-Vance, PhD, APRN, AOCN®, nurse practitioner and quality-of-life researcher at Moffitt Cancer Center in Tampa, FL, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about myelodysplastic syndrome (MDS) treatment considerations. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 15, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge about the treatment considerations for MDS. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 411: An Overview of Myelodysplastic Syndrome for Oncology Nurses Episode 256: Cancer Symptom Management Basics: Hematologic Complications ONS Voice articles: FDA Approves Luspatercept-Aamt for Anemia in Adults With MDS Infection Prevention for Oncology Nurses Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents Whole-Genome Sequencing May Guide Treatment Choices for AML and MDS Clinical Journal of Oncology Nursing articles:  Reducing Effects of Hospital-Associated Deconditioning in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Resilience in Older Adults Diagnosed With Cancer and Receiving Chemotherapy Targeted Drug Therapies: Beyond Blood Counts and Chemistries Oncology Nursing Forum article: Frailty in Patients With Hematologic Malignancies and Those Undergoing Transplantation: A Scoping Review ONS books:  BMTCN™ Certification Review Manual (second edition) Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) ONS course: Hematopoietic Stem Cell Transplantation™ ONS Learning Library: Hematology, Cellular Therapy, and Stem Cell Transplantation ONS Symptom Intervention resources: Prevention of Infection: General Prevention of Infection: Transplant Aplastic Anemia and MDS International Foundation: MDS Drugs and Treatments Blood Cancer United: MDS Treatment HealthTree Foundation Myelodysplastic Syndromes Foundation To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The goals that I try to consolidate to make sure they're consistent with the patient's goals are to improve their counts, especially the anemia or cytopenias. If they're getting blood transfusions, we want to reduce the number of transfusions that they receive because we know that's linked to reduced overall survival, and it really impacts quality of life. ... And then for high-risk patients, it's a more serious discussion because we know that they are the ones who can progress to acute myeloid leukemia (AML). And we're trying to delay progression to AML. That means we're trying to improve their survival and we're also trying to manage their cytopenias and decrease their infection risk." TS 2:28 "If we look at approvals for low-risk disease and high-risk disease, those were really made based on the Revised International Prognostic Scoring System (IPSS-R) and sometimes the International Prognostic Scoring System (IPSS). Under those classification systems, when we think of lower-risk MDS, we think of patients who are primarily anemic but don't have increased blasts in their bone marrow. ... For higher-risk MDS, we want to have that discussion with those patients because their life expectancy is much shorter than patients with lower-risk MDS. We want to see if hematopoietic stem cell transplant would be something that they would be interested in if they don't have a lot of comorbidities and are relatively healthy." TS 11:41 "There are a lot of things to consider—[patients'] blood counts, comorbidities, whether they're frail, and what their goals are. There are some patients where there's no way they would want to go through transplant. And some patients want to be cured, so it just depends on your patient." TS 14:22 "I think of hematopoietic allogeneic transplants as a treatment for more of the patients with higher-risk MDS. ... With the Molecular International Prognostic Scoring System (IPSS-M), a patient can have pretty good blood counts and not have increased blasts in the bone marrow. You could send them for a transplant referral upfront without having to give them additional treatment. ... There is a recent publication that said if a patient doesn't have more than 10% blast, you could refer to transplant as a first option. ... Also, if you had a lower-risk patient who is relatively young and doesn't have any other treatment options, this would also be a patient that you could refer to transplant to see if we could care for them, and then they wouldn't have to be getting transfused all the time." TS 21:12 "I think that we often think low-risk, no treatment needed, but it depends on the person. They often need ongoing supportive care to manage their symptoms even if they're not getting treatment. And just because we're not treating them, active observation, bringing them in to see how they're doing, if they've had infections, if their blood counts are changing, that is paying attention to them and doing something. Just because they're low-risk doesn't mean they don't need anything and we can just schedule for a one-year follow-up." TS 26:30